http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://www.merit.com/20240930#BusinessCombinationContingentConsiderationArrangementsContingentConsiderationBenefit http://www.merit.com/20240930#BusinessCombinationContingentConsiderationArrangementsContingentConsiderationBenefit http://www.merit.com/20240930#BusinessCombinationContingentConsiderationArrangementsContingentConsiderationBenefit 0000856982--12-31 2024 Q3 false MERIT MEDICAL SYSTEMS INC 58274000 57858000 http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent P5D P10D P10D P20D P30D P20D P30D http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://www.merit.com/20240930#BusinessCombinationContingentConsiderationArrangementsContingentConsiderationBenefit 0000856982 us-gaap:RetainedEarningsMember 2024-09-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000856982 us-gaap:RetainedEarningsMember 2024-06-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-30 0000856982 us-gaap:RetainedEarningsMember 2024-03-31 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000856982 2024-03-31 0000856982 us-gaap:RetainedEarningsMember 2023-12-31 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000856982 us-gaap:RetainedEarningsMember 2023-09-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000856982 us-gaap:RetainedEarningsMember 2023-06-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0000856982 us-gaap:RetainedEarningsMember 2023-03-31 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000856982 2023-03-31 0000856982 us-gaap:RetainedEarningsMember 2022-12-31 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000856982 srt:MaximumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000856982 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0000856982 mmsi:CashSettledPerformanceSharesMember 2023-12-31 0000856982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-09-30 0000856982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0000856982 mmsi:BluegrassVascularTechnologiesIncMember 2024-01-01 2024-09-30 0000856982 mmsi:PeripheralInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:PeripheralInterventionMember country:US mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:OEMMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:OEMMember country:US mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:EndoscopyDevicesMember us-gaap:NonUsMember mmsi:EndoscopySegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:EndoscopyDevicesMember country:US mmsi:EndoscopySegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:CustomProceduralSolutionsMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:CustomProceduralSolutionsMember country:US mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:CardiacInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:CardiacInterventionMember country:US mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:PeripheralInterventionMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:OEMMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:EndoscopyDevicesMember mmsi:EndoscopySegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:CustomProceduralSolutionsMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:CardiacInterventionMember mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 country:US mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 us-gaap:NonUsMember 2024-07-01 2024-09-30 0000856982 country:US 2024-07-01 2024-09-30 0000856982 mmsi:PeripheralInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:PeripheralInterventionMember country:US mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:OEMMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:OEMMember country:US mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:EndoscopyDevicesMember us-gaap:NonUsMember mmsi:EndoscopySegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:EndoscopyDevicesMember country:US mmsi:EndoscopySegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:CustomProceduralSolutionsMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:CustomProceduralSolutionsMember country:US mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:CardiacInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:CardiacInterventionMember country:US mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:PeripheralInterventionMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:OEMMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:EndoscopyDevicesMember mmsi:EndoscopySegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:CustomProceduralSolutionsMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:CardiacInterventionMember mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 country:US mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 us-gaap:NonUsMember 2024-01-01 2024-09-30 0000856982 country:US 2024-01-01 2024-09-30 0000856982 mmsi:PeripheralInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:PeripheralInterventionMember country:US mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:OEMMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:OEMMember country:US mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:EndoscopyDevicesMember us-gaap:NonUsMember mmsi:EndoscopySegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:EndoscopyDevicesMember country:US mmsi:EndoscopySegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:CustomProceduralSolutionsMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:CustomProceduralSolutionsMember country:US mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:CardiacInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:CardiacInterventionMember country:US mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:PeripheralInterventionMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:OEMMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:EndoscopyDevicesMember mmsi:EndoscopySegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:CustomProceduralSolutionsMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:CardiacInterventionMember mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 country:US mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 us-gaap:NonUsMember 2023-07-01 2023-09-30 0000856982 country:US 2023-07-01 2023-09-30 0000856982 mmsi:PeripheralInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:PeripheralInterventionMember country:US mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:OEMMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:OEMMember country:US mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:EndoscopyDevicesMember us-gaap:NonUsMember mmsi:EndoscopySegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:EndoscopyDevicesMember country:US mmsi:EndoscopySegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:CustomProceduralSolutionsMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:CustomProceduralSolutionsMember country:US mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:CardiacInterventionMember us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:CardiacInterventionMember country:US mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 us-gaap:NonUsMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:PeripheralInterventionMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:OEMMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:EndoscopyDevicesMember mmsi:EndoscopySegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:CustomProceduralSolutionsMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:CardiacInterventionMember mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 country:US mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 us-gaap:NonUsMember 2023-01-01 2023-09-30 0000856982 country:US 2023-01-01 2023-09-30 0000856982 mmsi:CookMedicalHoldingsLlcMember us-gaap:SubsequentEventMember 2024-10-01 2024-12-31 0000856982 mmsi:ScholtenSurgicalInstrumentsIncMember 2024-03-08 2024-03-08 0000856982 mmsi:MeritMedicalIrelandLimitedMember mmsi:CrannmedLimitedMember 2024-05-17 2024-05-17 0000856982 mmsi:FluidxMedicalTechnologyLLCMember 2024-03-01 2024-03-31 0000856982 mmsi:FluidxMedicalTechnologyLLCMember 2019-01-01 2021-12-31 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2024-07-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:RevenueFromContractWithCustomerMember 2024-07-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2024-01-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:RevenueFromContractWithCustomerMember 2024-01-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:RevenueFromContractWithCustomerMember 2023-07-01 2023-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-07-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2024-07-01 2024-09-30 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-09-30 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0000856982 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0000856982 mmsi:EndoscopySegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:CardiovascularSegmentMember 2024-07-01 2024-09-30 0000856982 mmsi:EndoscopySegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:CardiovascularSegmentMember 2023-07-01 2023-09-30 0000856982 mmsi:EndoscopySegmentMember 2023-01-01 2023-09-30 0000856982 mmsi:CardiovascularSegmentMember 2023-01-01 2023-09-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-01 2024-09-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-01 2024-09-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 2023-09-30 0000856982 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000856982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000856982 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000856982 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000856982 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000856982 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000856982 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000856982 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000856982 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000856982 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000856982 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000856982 mmsi:CreditAgreementMember 2023-12-31 0000856982 mmsi:CreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2023-06-06 0000856982 mmsi:SoloPaceIncMember 2024-01-01 2024-09-30 0000856982 mmsi:SelioMedicalLimitedSelioMember 2024-01-01 2024-09-30 0000856982 mmsi:FluidxMedicalTechnologyLLCMember 2024-01-01 2024-09-30 0000856982 mmsi:EndoscopySegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:EndoscopySegmentMember 2024-09-30 0000856982 mmsi:CardiovascularSegmentMember 2024-09-30 0000856982 mmsi:CardiovascularSegmentMember 2023-12-31 0000856982 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000856982 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000856982 srt:WeightedAverageMember mmsi:EndoGastricSolutionsIncMember 2024-07-01 0000856982 srt:WeightedAverageMember mmsi:AngioDynamicsIncMember 2023-06-08 0000856982 srt:WeightedAverageMember mmsi:BluegrassVascularTechnologiesIncMember 2023-05-04 0000856982 us-gaap:TrademarksMember 2024-09-30 0000856982 us-gaap:PatentsMember 2024-09-30 0000856982 us-gaap:OtherIntangibleAssetsMember 2024-09-30 0000856982 us-gaap:LicensingAgreementsMember 2024-09-30 0000856982 us-gaap:DistributionRightsMember 2024-09-30 0000856982 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000856982 us-gaap:CustomerListsMember 2024-09-30 0000856982 us-gaap:TrademarksMember 2023-12-31 0000856982 us-gaap:PatentsMember 2023-12-31 0000856982 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000856982 us-gaap:LicensingAgreementsMember 2023-12-31 0000856982 us-gaap:DistributionRightsMember 2023-12-31 0000856982 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000856982 us-gaap:CustomerListsMember 2023-12-31 0000856982 mmsi:SelioMedicalLimitedSelioMember 2024-09-30 0000856982 2024-06-30 0000856982 mmsi:SelioMedicalLimitedSelioMember 2023-12-31 0000856982 2023-06-30 0000856982 mmsi:ContingentConsiderationMember 2024-09-30 0000856982 mmsi:ContingentConsiderationMember 2024-06-30 0000856982 mmsi:ContingentConsiderationMember 2023-12-31 0000856982 mmsi:ContingentConsiderationMember 2023-09-30 0000856982 mmsi:ContingentConsiderationMember 2023-06-30 0000856982 mmsi:ContingentConsiderationMember 2022-12-31 0000856982 mmsi:ContingentConsiderationMember 2024-07-01 2024-09-30 0000856982 mmsi:ContingentConsiderationMember 2024-01-01 2024-09-30 0000856982 mmsi:ContingentConsiderationMember 2023-07-01 2023-09-30 0000856982 mmsi:ContingentConsiderationMember 2023-01-01 2023-09-30 0000856982 mmsi:MeritMedicalIrelandLimitedMember mmsi:CrannmedLimitedMember 2024-05-17 0000856982 mmsi:FluidxMedicalTechnologyLLCMember 2024-03-31 0000856982 mmsi:BluegrassVascularTechnologiesIncMember 2023-01-01 2023-09-30 0000856982 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0000856982 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000856982 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0000856982 us-gaap:PerformanceSharesMember 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember 2024-09-30 0000856982 mmsi:CashSettledPerformanceSharesMember 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember 2024-01-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueHedgingMember us-gaap:NondesignatedMember 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueHedgingMember us-gaap:NondesignatedMember 2023-12-31 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-07-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-01-01 2024-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-07-01 2023-09-30 0000856982 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-01-01 2023-09-30 0000856982 mmsi:WellsFargoFixedRateDerivativeContractTwoMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-23 0000856982 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000856982 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0000856982 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000856982 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000856982 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0000856982 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000856982 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0000856982 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000856982 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000856982 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000856982 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0000856982 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000856982 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000856982 us-gaap:ConvertibleNotesPayableMember mmsi:SeniorUnsecuredConvertibleNotesMember us-gaap:CallOptionMember 2023-12-31 0000856982 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000856982 us-gaap:ConvertibleNotesPayableMember mmsi:SeniorUnsecuredConvertibleNotesMember 2023-12-31 0000856982 mmsi:CreditAgreementMember us-gaap:LoansPayableMember 2023-06-06 0000856982 us-gaap:ConvertibleNotesPayableMember mmsi:SeniorUnsecuredConvertibleNotesMember us-gaap:CommonStockMember 2024-09-30 0000856982 us-gaap:ConvertibleNotesPayableMember mmsi:SeniorUnsecuredConvertibleNotesMember us-gaap:CommonStockMember 2023-12-31 0000856982 us-gaap:LoansPayableMember 2024-09-30 0000856982 us-gaap:ConvertibleNotesPayableMember 2024-09-30 0000856982 mmsi:CreditAgreementMember 2024-09-30 0000856982 us-gaap:LoansPayableMember 2023-12-31 0000856982 us-gaap:ConvertibleNotesPayableMember 2023-12-31 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-01 2024-09-30 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-30 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 2023-09-30 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000856982 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000856982 us-gaap:CommonStockMember 2024-09-30 0000856982 us-gaap:CommonStockMember 2024-06-30 0000856982 us-gaap:CommonStockMember 2024-03-31 0000856982 us-gaap:CommonStockMember 2023-12-31 0000856982 us-gaap:CommonStockMember 2023-09-30 0000856982 us-gaap:CommonStockMember 2023-06-30 0000856982 us-gaap:CommonStockMember 2023-03-31 0000856982 us-gaap:CommonStockMember 2022-12-31 0000856982 2022-12-31 0000856982 2023-09-30 0000856982 mmsi:BluegrassVascularTechnologiesIncMember 2023-05-04 0000856982 mmsi:EndoGastricSolutionsIncMember us-gaap:TrademarksMember 2024-07-01 0000856982 mmsi:EndoGastricSolutionsIncMember us-gaap:DevelopedTechnologyRightsMember 2024-07-01 0000856982 mmsi:EndoGastricSolutionsIncMember us-gaap:CustomerListsMember 2024-07-01 0000856982 mmsi:AngioDynamicsIncMember us-gaap:TrademarksMember 2023-06-08 0000856982 mmsi:AngioDynamicsIncMember us-gaap:DevelopedTechnologyRightsMember 2023-06-08 0000856982 mmsi:AngioDynamicsIncMember us-gaap:CustomerListsMember 2023-06-08 0000856982 mmsi:BluegrassVascularTechnologiesIncMember us-gaap:TrademarksMember 2023-05-04 0000856982 mmsi:BluegrassVascularTechnologiesIncMember us-gaap:DevelopedTechnologyRightsMember 2023-05-04 0000856982 mmsi:AngioDynamicsIncMember 2023-06-08 0000856982 mmsi:EndoGastricSolutionsIncMember 2024-07-01 2024-09-30 0000856982 mmsi:AngioDynamicsIncMember 2024-01-01 2024-09-30 0000856982 mmsi:AngioDynamicsIncMember 2023-01-01 2023-09-30 0000856982 srt:WeightedAverageMember mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2024-09-30 0000856982 srt:MinimumMember mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2024-09-30 0000856982 srt:MaximumMember mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2024-09-30 0000856982 mmsi:RevenueMilestonesMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2024-09-30 0000856982 mmsi:RegulatoryApprovalMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2024-09-30 0000856982 mmsi:RegulatoryApprovalMilestoneMember us-gaap:FairValueInputsLevel3Member mmsi:MilestonePaymentProbabilityMember us-gaap:IncomeApproachValuationTechniqueMember 2024-09-30 0000856982 srt:WeightedAverageMember mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0000856982 srt:MinimumMember mmsi:RevenueMilestonesMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0000856982 srt:MinimumMember mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0000856982 srt:MaximumMember mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0000856982 mmsi:RegulatoryApprovalMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0000856982 mmsi:RegulatoryApprovalMilestoneMember us-gaap:FairValueInputsLevel3Member mmsi:MilestonePaymentProbabilityMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0000856982 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000856982 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000856982 mmsi:RevenueMilestonesMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0000856982 mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0000856982 mmsi:RegulatoryApprovalMilestoneMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0000856982 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000856982 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000856982 mmsi:RevenueMilestonesMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000856982 mmsi:RevenueBasedPaymentsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000856982 mmsi:RegulatoryApprovalMilestoneMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000856982 mmsi:EndoGastricSolutionsIncMember 2024-07-01 2024-07-01 0000856982 mmsi:AngioDynamicsIncMember 2023-06-08 2023-06-08 0000856982 mmsi:BluegrassVascularTechnologiesIncMember 2023-05-04 2023-05-04 0000856982 mmsi:EndoGastricSolutionsIncMember 2024-01-01 2024-09-30 0000856982 mmsi:AngioDynamicsIncMember 2023-01-01 2023-12-31 0000856982 mmsi:ScholtenSurgicalInstrumentsIncMember mmsi:ContingentConsiderationPaymentTwoMember 2024-03-08 2024-03-08 0000856982 mmsi:ScholtenSurgicalInstrumentsIncMember mmsi:ContingentConsiderationPaymentThreeMember 2024-03-08 2024-03-08 0000856982 mmsi:ScholtenSurgicalInstrumentsIncMember mmsi:ContingentConsiderationPaymentOneMember 2024-03-08 2024-03-08 0000856982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0000856982 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0000856982 mmsi:CashSettledPerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0000856982 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0000856982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0000856982 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0000856982 mmsi:CashSettledPerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0000856982 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0000856982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000856982 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000856982 mmsi:CashSettledPerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000856982 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000856982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000856982 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000856982 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000856982 mmsi:CashSettledPerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000856982 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000856982 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000856982 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000856982 2024-04-01 2024-06-30 0000856982 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000856982 2023-04-01 2023-06-30 0000856982 mmsi:CookMedicalHoldingsLlcMember us-gaap:SubsequentEventMember 2024-12-31 0000856982 2024-01-01 2024-03-31 0000856982 2023-01-01 2023-03-31 0000856982 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000856982 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000856982 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000856982 mmsi:CashSettledPerformanceSharesMember 2024-01-01 2024-09-30 0000856982 mmsi:CashSettledPerformanceSharesMember 2023-01-01 2023-09-30 0000856982 srt:MaximumMember mmsi:CashSettledPerformanceSharesMember 2024-01-01 2024-09-30 0000856982 srt:MaximumMember mmsi:CashSettledPerformanceSharesMember 2023-01-01 2023-09-30 0000856982 mmsi:CardiovascularSegmentMember 2024-01-01 2024-09-30 0000856982 mmsi:CreditAgreementMember 2024-01-01 2024-09-30 0000856982 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember mmsi:SeniorUnsecuredConvertibleNotesMember 2023-12-01 2023-12-31 0000856982 2024-09-30 0000856982 2023-12-31 0000856982 mmsi:BluegrassVascularTechnologiesIncMember 2023-05-03 0000856982 mmsi:MeritMedicalIrelandLimitedMember mmsi:CrannmedLimitedMember mmsi:EquityMethodInvestmentAdditionalPreferenceSharesMember 2024-05-17 0000856982 mmsi:MeritMedicalIrelandLimitedMember mmsi:CrannmedLimitedMember mmsi:EquityMethodInvestmentAdditionalFundingMember 2024-05-17 0000856982 us-gaap:ConvertibleNotesPayableMember mmsi:SeniorUnsecuredConvertibleNotesMember us-gaap:CallOptionMember 2023-12-01 2023-12-31 0000856982 us-gaap:ConvertibleNotesPayableMember mmsi:SeniorUnsecuredConvertibleNotesMember 2023-12-01 2023-12-31 0000856982 mmsi:RevenueAndCostOfSalesMember 2024-01-01 2024-09-30 0000856982 mmsi:EndoGastricSolutionsIncMember 2024-07-01 0000856982 us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-30 0000856982 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0000856982 us-gaap:AccruedLiabilitiesMember 2024-09-30 0000856982 us-gaap:AccruedLiabilitiesMember 2023-12-31 0000856982 2023-07-01 2023-09-30 0000856982 mmsi:ScholtenSurgicalInstrumentsIncMember 2024-03-08 0000856982 2023-01-01 2023-09-30 0000856982 2024-07-01 2024-09-30 0000856982 2024-10-28 0000856982 2024-01-01 2024-09-30 xbrli:shares iso4217:USD mmsi:item xbrli:pure iso4217:EUR iso4217:USD xbrli:shares iso4217:USD mmsi:derivative mmsi:segment

Table of Contents

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number 0-18592

​

MERIT MEDICAL SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

​

Utah |  | 87-0447695
(State or other jurisdiction of incorporation or organization) | ​ | (IRS Employer Identification No.)

​

1600 West Merit Parkway, South Jordan, Utah 84095

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (801) 253-1600

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​
Title of each class | Trading Symbol | Name of exchange on which registered
Common Stock, no par value | MMSI | NASDAQ Global Select Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☒ | Accelerated Filer ☐ | Non-Accelerated Filer ☐ | Smaller Reporting Company ☐ | Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of the latest practicable date.

​

Title or class | ​ | Shares outstanding as of October 28, 2024
Common Stock, no par value |  | 58,279,409

​

​

​

Table of Contents

​

​

​

​

​

TABLE OF CONTENTS

​

PART I. |  | ​ | ​ | FINANCIAL INFORMATION | ​ ​ 3
​ | ​ | ​ | ​ | ​ | ​
Item 1. | ​ | ​ | ​ | Financial Statements (Unaudited) | 3
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Consolidated Balance Sheets | 3
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Consolidated Statements of Income | 5
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Consolidated Statements of Comprehensive Income | 6
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Consolidated Statements of Stockholders’ Equity | 7
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Consolidated Statements of Cash Flows | 9
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Condensed Notes to Consolidated Financial Statements | 11
​ | ​ | ​ | ​ | ​ | ​
Item 2. | ​ | ​ | ​ | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 33
​ | ​ | ​ | ​ | ​ | ​
Item 3. | ​ | ​ | ​ | Quantitative and Qualitative Disclosures About Market Risk | 41
​ | ​ | ​ | ​ | ​ | ​
Item 4. | ​ | ​ | ​ | Controls and Procedures | 42
​ | ​ | ​ | ​ | ​ | ​
PART II. | ​ | ​ | ​ | OTHER INFORMATION | 42
​ | ​ | ​ | ​ | ​ | ​
Item 1. | ​ | ​ | ​ | Legal Proceedings | 42
​ | ​ | ​ | ​ | ​ | ​
Item 1A. | ​ | ​ | ​ | Risk Factors | 42
​ | ​ | ​ | ​ | ​ | ​
Item 5. | ​ | ​ | ​ | Other information | 43
​ | ​ | ​ | ​ | ​ | ​
Item 6. | ​ | ​ | ​ | Exhibits | 44
​ | ​ | ​ | ​ | ​ | ​
SIGNATURES | ​ | ​ | ​ | 45

​

​

​

​

​

​

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
ASSETS |  | 2024 |  | 2023
​ | ​ | ​ | (unaudited) | ​ | ​ | ​
Current assets: |  | ​ |  |  | ​ |
Cash and cash equivalents | ​ | $ | 523,128 | ​ | $ | 587,036
Trade receivables — net of allowance for credit losses — 2024 — $9,266 and 2023 — $9,023 | ​ |  | 189,831 | ​ |  | 177,885
Other receivables | ​ |  | 15,325 | ​ |  | 10,517
Inventories | ​ |  | 310,527 | ​ |  | 303,871
Prepaid expenses and other current assets | ​ |  | 27,105 | ​ |  | 24,286
Prepaid income taxes | ​ |  | 4,216 | ​ |  | 4,016
Income tax refund receivables | ​ |  | 8,185 | ​ |  | 859
Total current assets | ​ |  | 1,078,317 | ​ |  | 1,108,470
​ | ​ | ​ | ​ | ​ | ​ | ​
Property and equipment: | ​ |  |  | ​ |  |
Land and land improvements | ​ |  | 26,108 | ​ |  | 26,017
Buildings | ​ |  | 192,323 | ​ |  | 191,491
Manufacturing equipment | ​ |  | 334,787 | ​ |  | 316,930
Furniture and fixtures | ​ |  | 66,593 | ​ |  | 63,044
Leasehold improvements | ​ |  | 59,005 | ​ |  | 53,638
Construction-in-progress | ​ |  | 66,699 | ​ |  | 61,439
Total property and equipment | ​ |  | 745,515 | ​ |  | 712,559
Less accumulated depreciation | ​ |  | (355,862) | ​ |  | (329,036)
Property and equipment — net | ​ |  | 389,653 | ​ | ​ | 383,523
​ | ​ | ​ | ​ | ​ | ​ | ​
Other assets: | ​ |  |  | ​ |  |
Intangible assets: | ​ |  |  | ​ |  |
Developed technology — net of accumulated amortization — 2024 — $361,725 and 2023 — $321,488 | ​ |  | 322,325 | ​ |  | 283,999
Other — net of accumulated amortization — 2024 — $82,979 and 2023 — $76,887 | ​ |  | 49,839 | ​ |  | 41,884
Goodwill | ​ |  | 399,448 | ​ |  | 382,240
Deferred income tax assets | ​ |  | 7,253 | ​ |  | 7,288
Right-of-use operating lease assets | ​ | ​ | 68,867 | ​ | ​ | 63,047
Other assets | ​ |  | 62,382 | ​ |  | 54,793
Total other assets | ​ |  | 910,114 | ​ |  | 833,251
​ | ​ | ​ | ​ | ​ | ​ | ​
Total assets | ​ | $ | 2,378,084 | ​ | $ | 2,325,244

​

​ | ​
See condensed notes to consolidated financial statements. | (continued)

​

​

​

3

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
LIABILITIES AND STOCKHOLDERS’ EQUITY |  | 2024 |  | 2023
​ | ​ | ​ | (unaudited) | ​ | ​ | ​
Current liabilities: |  | ​ |  | ​ | ​ |
Trade payables | ​ | $ | 60,808 | ​ | $ | 65,944
Accrued expenses | ​ |  | 127,255 | ​ |  | 120,447
Short-term operating lease liabilities | ​ | ​ | 11,469 | ​ | ​ | 12,087
Income taxes payable | ​ |  | 1,547 | ​ |  | 5,086
Total current liabilities | ​ |  | 201,079 | ​ |  | 203,564
​ | ​ | ​ | ​ | ​ | ​ | ​
Long-term debt | ​ |  | 750,505 | ​ |  | 823,013
Deferred income tax liabilities | ​ |  | 5,571 | ​ |  | 5,547
Long-term income taxes payable | ​ |  | 347 | ​ |  | 347
Liabilities related to unrecognized tax benefits | ​ |  | 1,912 | ​ |  | 1,912
Deferred compensation payable | ​ |  | 19,218 | ​ |  | 17,167
Deferred credits | ​ |  | 1,527 | ​ |  | 1,605
Long-term operating lease liabilities | ​ | ​ | 57,178 | ​ |  | 56,259
Other long-term obligations | ​ |  | 17,341 | ​ |  | 13,830
Total liabilities | ​ |  | 1,054,678 | ​ |  | 1,123,244
​ | ​ | ​ | ​ | ​ | ​ | ​
Commitments and contingencies | ​ |  |  | ​ |  |
​ | ​ | ​ | ​ | ​ | ​ | ​
Stockholders' equity: | ​ |  |  | ​ |  |
Preferred stock — 5,000 shares authorized; no shares issued as of September 30, 2024 and December 31, 2023 | ​ |  | — | ​ |  | —
Common stock, no par value — 100,000 shares authorized; issued and outstanding as of September 30, 2024 - 58,274 and December 31, 2023 - 57,858 | ​ |  | 669,207 | ​ |  | 638,150
Retained earnings | ​ |  | 667,594 | ​ |  | 575,184
Accumulated other comprehensive loss | ​ |  | (13,395) | ​ |  | (11,334)
Total stockholders’ equity | ​ |  | 1,323,406 | ​ |  | 1,202,000
​ | ​ | ​ | ​ | ​ | ​ | ​
Total liabilities and stockholders’ equity | ​ | $ | 2,378,084 | ​ | $ | 2,325,244

​

​ | ​
See condensed notes to consolidated financial statements. | (concluded)

​

​

​

4

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share amounts - unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended |  | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ |  | 2024 |  | 2023 |  | 2024 |  | 2023 | ​
Net sales | ​ | $ | 339,845 | ​ | $ | 315,230 | ​ | $ | 1,001,356 | ​ | $ | 932,851 | ​
Cost of sales | ​ |  | 182,310 | ​ |  | 173,031 | ​ |  | 531,006 | ​ |  | 499,508 | ​
Gross profit | ​ |  | 157,535 | ​ |  | 142,199 | ​ |  | 470,350 | ​ |  | 433,343 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating expenses: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Selling, general and administrative | ​ |  | 99,644 | ​ |  | 86,854 | ​ |  | 288,657 | ​ |  | 277,925 | ​
Research and development | ​ |  | 20,527 | ​ |  | 19,646 | ​ |  | 62,272 | ​ |  | 61,089 | ​
Impairment charges | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 270 | ​
Contingent consideration expense | ​ |  | 103 | ​ |  | 562 | ​ |  | 292 | ​ |  | 2,177 | ​
Acquired in-process research and development | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 1,550 | ​
Total operating expenses | ​ |  | 120,274 | ​ |  | 107,062 | ​ |  | 351,221 | ​ |  | 343,011 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income from operations | ​ |  | 37,261 | ​ |  | 35,137 | ​ |  | 119,129 | ​ |  | 90,332 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other income (expense): | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Interest income | ​ |  | 6,652 | ​ |  | 181 | ​ |  | 21,489 | ​ |  | 533 | ​
Interest expense | ​ |  | (7,501) | ​ |  | (4,841) | ​ |  | (23,226) | ​ |  | (10,534) | ​
Other income (expense) — net | ​ |  | 245 | ​ |  | (255) | ​ |  | (544) | ​ |  | 291 | ​
Total other expense — net | ​ |  | (604) | ​ |  | (4,915) | ​ |  | (2,281) | ​ |  | (9,710) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income before income taxes | ​ |  | 36,657 | ​ |  | 30,222 | ​ |  | 116,848 | ​ |  | 80,622 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income tax expense | ​ |  | 8,213 | ​ |  | 4,388 | ​ |  | 24,438 | ​ |  | 13,840 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 28,444 | ​ | $ | 25,834 | ​ | $ | 92,410 | ​ | $ | 66,782 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Earnings per common share | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Basic | ​ | $ | 0.49 | ​ | $ | 0.45 | ​ | $ | 1.59 | ​ | $ | 1.16 | ​
Diluted | ​ | $ | 0.48 | ​ | $ | 0.44 | ​ | $ | 1.57 | ​ | $ | 1.14 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average shares outstanding | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Basic | ​ |  | 58,231 | ​ |  | 57,682 | ​ |  | 58,110 | ​ |  | 57,525 | ​
Diluted | ​ |  | 59,537 | ​ |  | 58,375 | ​ |  | 58,948 | ​ |  | 58,345 | ​

​

See condensed notes to consolidated financial statements.

​

​

5

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands - unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended |  | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ |  | 2024 |  | 2023 |  | 2024 |  | 2023 | ​
Net income | ​ | $ | 28,444 | ​ | $ | 25,834 | ​ | $ | 92,410 | ​ | $ | 66,782 | ​
Other comprehensive income (loss): | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Cash flow hedges | ​ |  | (6,585) | ​ |  | (539) | ​ |  | (5,324) | ​ |  | 1,192 | ​
Income tax benefit (expense) | ​ |  | 1,555 | ​ |  | 129 | ​ |  | 1,257 | ​ |  | (286) | ​
Foreign currency translation adjustment | ​ |  | 7,153 | ​ |  | (2,914) | ​ |  | 2,061 | ​ |  | (2,190) | ​
Income tax benefit (expense) | ​ |  | (89) | ​ |  | 17 | ​ |  | (55) | ​ |  | (17) | ​
Total other comprehensive income (loss) | ​ |  | 2,034 | ​ |  | (3,307) | ​ |  | (2,061) | ​ |  | (1,301) | ​
Total comprehensive income | ​ | $ | 30,478 | ​ | $ | 22,527 | ​ | $ | 90,349 | ​ | $ | 65,481 | ​

​

See condensed notes to consolidated financial statements.

​

​

6

Table of Contents

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands - unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Retained | ​ | Accumulated Other | ​ | ​ | ​
​ |  | Shares |  | Amount |  | Earnings |  | Comprehensive Loss |  | Total
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance — January 1, 2024 |  | 57,858 | ​ | $ | 638,150 | ​ | $ | 575,184 | ​ | $ | (11,334) | ​ | $ | 1,202,000
Net income |  |  | ​ |  |  | ​ |  | 28,240 | ​ |  |  | ​ |  | 28,240
Other comprehensive loss |  |  | ​ |  |  | ​ |  |  | ​ |  | (1,122) | ​ |  | (1,122)
Stock-based compensation expense |  |  | ​ |  | 4,934 | ​ |  |  | ​ |  |  | ​ |  | 4,934
Options exercised |  | 213 | ​ |  | 7,394 | ​ |  |  | ​ |  |  | ​ |  | 7,394
Issuance of common stock under Employee Stock Purchase Plan |  | 5 | ​ |  | 336 | ​ |  |  | ​ |  |  | ​ |  | 336
Shares issued from time-vested restricted stock units | ​ | 47 | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | —
Shares surrendered in exchange for payment of payroll tax liabilities |  | (21) | ​ |  | (1,592) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,592)
Balance — March 31, 2024 |  | 58,102 | ​ | ​ | 649,222 | ​ | ​ | 603,424 | ​ | ​ | (12,456) | ​ | ​ | 1,240,190
Net income |  |  | ​ |  |  | ​ |  | 35,726 | ​ |  |  | ​ |  | 35,726
Other comprehensive loss |  |  | ​ |  |  | ​ |  |  | ​ |  | (2,973) | ​ |  | (2,973)
Stock-based compensation expense |  |  | ​ |  | 6,301 | ​ |  |  | ​ |  |  | ​ |  | 6,301
Options exercised |  | 66 | ​ |  | 2,913 | ​ |  |  | ​ |  |  | ​ |  | 2,913
Issuance of common stock under Employee Stock Purchase Plan |  | 4 | ​ |  | 288 | ​ |  |  | ​ |  |  | ​ |  | 288
Shares issued from time-vested restricted stock units | ​ | 20 | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | —
Balance — June 30, 2024 |  | 58,192 | ​ | ​ | 658,724 | ​ | ​ | 639,150 | ​ | ​ | (15,429) | ​ | ​ | 1,282,445
Net income |  |  | ​ |  |  | ​ |  | 28,444 | ​ |  |  | ​ |  | 28,444
Other comprehensive income |  |  | ​ |  |  | ​ |  |  | ​ |  | 2,034 | ​ |  | 2,034
Stock-based compensation expense |  |  | ​ |  | 5,990 | ​ |  |  | ​ |  |  | ​ |  | 5,990
Options exercised |  | 80 | ​ |  | 4,247 | ​ |  |  | ​ |  |  | ​ |  | 4,247
Issuance of common stock under Employee Stock Purchase Plan |  | 2 | ​ |  | 246 | ​ |  |  | ​ |  |  | ​ |  | 246
Balance — September 30, 2024 |  | 58,274 | ​ | $ | 669,207 | ​ | $ | 667,594 | ​ | $ | (13,395) | ​ | $ | 1,323,406

​

See condensed notes to consolidated financial statements. | (continued)

​

7

Table of Contents

​

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands - unaudited)

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Retained | ​ | Accumulated Other | ​ | ​ | ​
​ |  | Shares |  | Amount |  | Earnings |  | Comprehensive Loss |  | Total
Balance — January 1, 2023 |  | 57,306 | ​ | $ | 675,174 | ​ | $ | 480,773 | ​ | $ | (11,550) | ​ | $ | 1,144,397
Net income |  |  | ​ |  |  | ​ |  | 20,703 | ​ |  |  | ​ |  | 20,703
Other comprehensive income |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 621 | ​ |  | 621
Stock-based compensation expense |  | ​ | ​ |  | 3,498 | ​ |  | ​ | ​ |  | ​ | ​ |  | 3,498
Options exercised |  | 123 | ​ |  | 3,726 | ​ |  | ​ | ​ |  | ​ | ​ |  | 3,726
Issuance of common stock under Employee Stock Purchase Plan |  | 4 | ​ |  | 302 | ​ |  | ​ | ​ |  | ​ | ​ |  | 302
Shares issued from time-vested restricted stock units | ​ | 61 | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | —
Shares surrendered in exchange for payment of payroll tax liabilities |  | (22) | ​ |  | (1,592) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,592)
Balance — March 31, 2023 |  | 57,472 | ​ | ​ | 681,108 | ​ | ​ | 501,476 | ​ | ​ | (10,929) | ​ | ​ | 1,171,655
Net income |  |  | ​ |  |  | ​ |  | 20,245 | ​ |  |  | ​ |  | 20,245
Other comprehensive income |  |  | ​ |  |  | ​ |  |  | ​ |  | 1,385 | ​ |  | 1,385
Stock-based compensation expense |  |  | ​ |  | 4,980 | ​ |  |  | ​ |  |  | ​ |  | 4,980
Options exercised |  | 128 | ​ |  | 5,154 | ​ |  |  | ​ |  |  | ​ |  | 5,154
Issuance of common stock under Employee Stock Purchase Plan |  | 4 | ​ |  | 281 | ​ |  |  | ​ |  |  | ​ |  | 281
Shares issued from time-vested restricted stock units | ​ | 30 | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | —
Balance — June 30, 2023 | ​ | 57,634 | ​ | ​ | 691,523 | ​ | ​ | 521,721 | ​ | ​ | (9,544) | ​ | $ | 1,203,700
Net income |  |  | ​ |  |  | ​ |  | 25,834 | ​ |  |  | ​ |  | 25,834
Other comprehensive loss |  |  | ​ |  |  | ​ |  |  | ​ |  | (3,307) | ​ |  | (3,307)
Stock-based compensation expense |  |  | ​ |  | 5,206 | ​ |  |  | ​ |  |  | ​ |  | 5,206
Options exercised |  | 247 | ​ |  | 7,555 | ​ |  |  | ​ |  | ​ | ​ |  | 7,555
Issuance of common stock under Employee Stock Purchase Plan |  | 4 | ​ |  | 237 | ​ |  |  | ​ |  |  | ​ |  | 237
Shares surrendered in exchange for payment of payroll tax liabilities | ​ | (53) | ​ | ​ | (3,531) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (3,531)
Shares surrendered in exchange for exercise of stock options | ​ | (86) | ​ | ​ | (5,809) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (5,809)
Balance — September 30, 2023 | ​ | 57,746 | ​ | $ | 695,181 | ​ | $ | 547,555 | ​ | $ | (12,851) | ​ | $ | 1,229,885

​

​ | ​
​ See condensed notes to consolidated financial statements. | (concluded)
​ | ​
​ | ​

​

​

​

​

​

​

​

​

8

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands - unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended
​ | ​ | September 30,
​ |  | 2024 |  | 2023
CASH FLOWS FROM OPERATING ACTIVITIES: |  | ​ | ​ | ​
Net income | ​ | $ | 92,410 | ​ | $ | 66,782
Adjustments to reconcile net income to net cash provided by operating activities: | ​ |  |  | ​ |  |
Depreciation and amortization | ​ |  | 74,093 | ​ |  | 66,359
Loss on sale or abandonment of property and equipment | ​ |  | 215 | ​ |  | 4,761
Write-off of certain intangible assets and other long-term assets | ​ |  | 401 | ​ |  | 461
Acquired in-process research and development | ​ |  | — | ​ |  | 1,550
Amortization of right-of-use operating lease assets | ​ | ​ | 9,043 | ​ | ​ | 8,621
Fair value adjustments related to contingent consideration liabilities | ​ | ​ | 292 | ​ | ​ | 2,177
Amortization of deferred credits | ​ |  | (77) | ​ |  | (78)
Amortization of long-term debt issuance costs | ​ |  | 4,431 | ​ |  | 744
Stock-based compensation expense | ​ |  | 18,958 | ​ |  | 15,346
Changes in operating assets and liabilities, net of acquisitions and divestitures: | ​ |  | ​ | ​ |  | ​
Trade receivables | ​ |  | (9,540) | ​ |  | (3,852)
Other receivables | ​ |  | (4,670) | ​ |  | (1,040)
Inventories | ​ |  | (2,844) | ​ |  | (34,426)
Prepaid expenses and other current assets | ​ |  | (5,871) | ​ |  | (72)
Prepaid income taxes | ​ |  | — | ​ |  | (24)
Income tax refund receivables | ​ |  | (7,530) | ​ |  | (8,682)
Other assets | ​ |  | (3,860) | ​ |  | (719)
Trade payables | ​ |  | (6,489) | ​ |  | (20,332)
Accrued expenses | ​ |  | (614) | ​ |  | (599)
Income taxes payable | ​ |  | (2,246) | ​ |  | (3,431)
Deferred compensation payable | ​ |  | 2,051 | ​ |  | 245
Operating lease liabilities | ​ | ​ | (9,056) | ​ | ​ | (8,573)
Other long-term obligations | ​ |  | 2,958 | ​ |  | (2,318)
Total adjustments | ​ |  | 59,645 | ​ |  | 16,118
Net cash, cash equivalents, and restricted cash provided by operating activities | ​ |  | 152,055 | ​ |  | 82,900
​ | ​ | ​ | ​ | ​ | ​ | ​
CASH FLOWS FROM INVESTING ACTIVITIES: | ​ |  |  | ​ |  |
Capital expenditures for: | ​ |  |  | ​ |  |
Property and equipment | ​ |  | (31,668) | ​ |  | (27,151)
Intangible assets | ​ |  | (2,138) | ​ |  | (1,756)
Proceeds from the sale of property and equipment | ​ |  | 5 | ​ |  | 181
Issuance of note receivables | ​ |  | (6,662) | ​ |  | —
Cash paid in acquisitions and investments, net of cash acquired | ​ |  | (113,743) | ​ |  | (138,278)
Net cash, cash equivalents, and restricted cash used in investing activities | ​ | $ | (154,206) | ​ | $ | (167,004)

​

​ | ​
See condensed notes to consolidated financial statements. | (continued)

​

9

Table of Contents

​

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands - unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Nine Months Ended
​ | ​ | September 30,
​ | ​ | 2024 | ​ | 2023
CASH FLOWS FROM FINANCING ACTIVITIES: |  | ​ | ​ | ​
Proceeds from issuance of common stock | ​ | $ | 15,424 | ​ | $ | 11,446
Proceeds from issuance of long-term debt | ​ |  | — | ​ |  | 480,499
Payments on long-term debt | ​ | ​ | (76,063) | ​ | ​ | (391,624)
Long-term debt issuance costs | ​ |  | — | ​ |  | (5,240)
Contingent payments related to acquisitions | ​ |  | (209) | ​ |  | (3,502)
Payment of taxes related to an exchange of common stock | ​ |  | (1,592) | ​ |  | (5,123)
Net cash, cash equivalents, and restricted cash (used in) provided by financing activities | ​ |  | (62,440) | ​ |  | 86,456
Effect of exchange rates on cash, cash equivalents, and restricted cash | ​ |  | 724 | ​ |  | (2,181)
Net increase (decrease) in cash, cash equivalents and restricted cash | ​ |  | (63,867) | ​ |  | 171
​ | ​ | ​ | ​ | ​ | ​ | ​
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ​ |  |  | ​ |  |
Beginning of period | ​ | ​ | 589,144 | ​ | ​ | 60,558
End of period | ​ | $ | 525,277 | ​ | $ | 60,729
​ | ​ | ​ | ​ | ​ | ​ | ​
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | ​ | 523,128 | ​ | ​ | 58,673
Restricted cash reported in prepaid expenses and other current assets | ​ | ​ | 2,149 | ​ | ​ | 2,056
Total cash, cash equivalents and restricted cash | ​ | $ | 525,277 | ​ | $ | 60,729
​ | ​ | ​ | ​ | ​ | ​ | ​
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ​ |  |  | ​ |  |
Cash paid during the period for: | ​ |  |  | ​ |  |
Interest (net of capitalized interest of $712 and $941, respectively) | ​ | $ | 20,977 | ​ | $ | 9,572
Income taxes | ​ | ​ | 33,054 | ​ | ​ | 24,875
​ | ​ | ​ | ​ | ​ | ​ | ​
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ​ |  |  | ​ |  |
Property and equipment purchases in accounts payable | ​ | $ | 8,907 | ​ | $ | 4,613
Acquisition purchases in accrued expenses and other long-term obligations | ​ | ​ | 4,894 | ​ | ​ | 3,674
Merit common stock surrendered (0 and 86 shares, respectively) in exchange for exercise of stock options | ​ | ​ | — | ​ | ​ | 5,809
Right-of-use operating lease assets obtained in exchange for operating lease liabilities | ​ | ​ | 9,191 | ​ | ​ | 7,560

​

​ | ​
See condensed notes to consolidated financial statements. | (concluded)

​

​

​

10

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation and Other Items. The interim consolidated financial statements of Merit Medical Systems, Inc. ("Merit," "we" or "us") for the three and nine-month periods ended September 30, 2024 and 2023 are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial position as of September 30, 2024 and December 31, 2023, and our results of operations and cash flows for the three and nine-month periods ended September 30, 2024 and 2023. The results of operations for the three and nine-month periods ended September 30, 2024 and 2023 are not necessarily indicative of the results for a full-year period. Amounts presented in this report are rounded, while percentages and earnings per share amounts presented are calculated from the underlying amounts. These interim consolidated financial statements should be read in conjunction with the financial statements and risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”).

2. Recently Issued Accounting Standards. In November 2023, the Financial Accounting Standards Board (“FASB’) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The provisions of this update must be applied retrospectively to all periods presented in the financial statements. We are currently assessing the anticipated impact of this standard on our consolidated financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve annual basis income tax disclosures related to (1) rate reconciliation, (2) income taxes paid, and (3) other disclosures related to pretax income (or loss) and income tax expense (or benefit) from continuing operations. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statement disclosures.

​

We currently believe there are no other issued and not yet effective accounting standards that are materially relevant to our financial statements.

​

3. Revenue from Contracts with Customers. We recognize revenue when a customer obtains control of promised goods. The amount of revenue recognized reflects the consideration we expect to receive in exchange for these goods. Our revenue recognition policies have not changed from those disclosed in Note 1 to our consolidated financial statements in Item 8 of the 2023 Annual Report on Form 10-K.

Disaggregation of Revenue

Our revenue is disaggregated based on reporting segment, product category and geographic region. We design, develop, manufacture and market medical products for interventional, diagnostic and therapeutic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer (“OEM”). Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures.

11

Table of Contents

​

The following tables present revenue from contracts with customers by reporting segment, product category and geographic region for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended
​ | ​ | September 30, 2024 | ​ | September 30, 2023
​ |  | United States |  | International |  | Total |  | United States |  | International |  | Total
Cardiovascular |  | ​ |  |  | ​ | ​ |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Peripheral Intervention | ​ | $ | 84,217 | ​ | $ | 53,715 | ​ | $ | 137,932 | ​ | $ | 78,617 | ​ | $ | 49,768 | ​ | $ | 128,385
Cardiac Intervention | ​ |  | 37,248 | ​ | ​ | 53,521 | ​ |  | 90,769 | ​ |  | 36,593 | ​ | ​ | 52,513 | ​ |  | 89,106
Custom Procedural Solutions | ​ |  | 30,774 | ​ | ​ | 19,994 | ​ |  | 50,768 | ​ |  | 29,602 | ​ | ​ | 19,022 | ​ |  | 48,624
OEM | ​ |  | 38,093 | ​ | ​ | 5,293 | ​ |  | 43,386 | ​ |  | 34,207 | ​ | ​ | 5,762 | ​ |  | 39,969
Total | ​ |  | 190,332 | ​ | ​ | 132,523 | ​ |  | 322,855 | ​ |  | 179,019 | ​ |  | 127,065 | ​ |  | 306,084
​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Endoscopy | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Endoscopy Devices | ​ |  | 16,160 | ​ |  | 830 | ​ |  | 16,990 | ​ |  | 8,486 | ​ |  | 660 | ​ |  | 9,146
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total | ​ | $ | 206,492 | ​ | $ | 133,353 | ​ | $ | 339,845 | ​ | $ | 187,505 | ​ | $ | 127,725 | ​ | $ | 315,230

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, 2024 | ​ | September 30, 2023
​ |  | United States |  | International |  | Total |  | United States |  | International |  | Total
Cardiovascular |  | ​ | ​ |  | ​ | ​ |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Peripheral Intervention | ​ | $ | 245,832 | ​ | $ | 165,973 | ​ | $ | 411,805 | ​ | $ | 219,257 | ​ | $ | 148,820 | ​ | $ | 368,077
Cardiac Intervention | ​ |  | 109,431 | ​ | ​ | 165,889 | ​ |  | 275,320 | ​ |  | 106,588 | ​ | ​ | 161,621 | ​ |  | 268,209
Custom Procedural Solutions | ​ |  | 90,564 | ​ | ​ | 59,414 | ​ |  | 149,978 | ​ |  | 85,556 | ​ | ​ | 60,153 | ​ |  | 145,709
OEM | ​ |  | 106,202 | ​ | ​ | 20,739 | ​ |  | 126,941 | ​ |  | 101,341 | ​ | ​ | 21,999 | ​ |  | 123,340
Total | ​ |  | 552,029 | ​ | ​ | 412,015 | ​ |  | 964,044 | ​ |  | 512,742 | ​ |  | 392,593 | ​ |  | 905,335
​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Endoscopy | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Endoscopy Devices | ​ |  | 35,221 | ​ |  | 2,091 | ​ |  | 37,312 | ​ |  | 25,705 | ​ |  | 1,811 | ​ |  | 27,516
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total | ​ | $ | 587,250 | ​ | $ | 414,106 | ​ | $ | 1,001,356 | ​ | $ | 538,447 | ​ | $ | 394,404 | ​ | $ | 932,851

​

​

​

4. Acquisitions and Investments. On July 1, 2024, we entered into an Asset Purchase Agreement (the “EGS Purchase Agreement”) with EndoGastric Solutions, Inc., a Delaware corporation (“EGS”), pursuant to which we acquired the EsophyX® Z+ device and various assets related thereto (collectively, the “EGS Acquisition”), which are designed to deliver a durable, minimally invasive non-pharmacological treatment option for patients suffering from gastroesophageal reflux disease. We acquired the purchased assets identified under the EGS Purchase Agreement for a purchase price of $105 million, which amount we financed at closing through current borrowings under our long-term debt obligations, plus the assumption or reimbursement of certain liabilities of EGS. We accounted for the EGS Acquisition under the acquisition method of accounting as a business combination. The sales related to the EGS Acquisition have been included in our endoscopy segment since the acquisition date and were $6.8 million for the three and nine-month periods ended September 30, 2024. It is not practical to separately report earnings related to the EGS Acquisition, as we began to immediately integrate the acquisition into the existing operations, sales distribution networks and management structure of our endoscopy business segment. Acquisition-related costs associated with the EGS Acquisition, which were included in selling, general and administrative expenses in the consolidated statements of income were approximately $1.8 million. The purchase price was preliminarily allocated as follows (in thousands):

​

12

Table of Contents

​ | ​ | ​ | ​
Assets Acquired |  | ​ |
Trade receivables | ​ | $ | 2,568
Inventories | ​ | ​ | 3,553
Prepaid expenses and other current assets | ​ | ​ | 99
Property and equipment | ​ | ​ | 258
Intangible assets | ​ |  | ​
Developed technology | ​ | ​ | 72,800
Trademarks | ​ | ​ | 5,400
Customer list | ​ | ​ | 6,600
Goodwill | ​ | ​ | 16,997
Total assets acquired | ​ |  | 108,275
​ | ​ | ​ | ​
Liabilities Assumed | ​ |  |
Trade payables | ​ |  | 494
Accrued expenses | ​ |  | 2,752
Total liabilities assumed | ​ |  | 3,246
​ | ​ | ​ | ​
Total net assets acquired | ​ | $ | 105,029

​

We are amortizing the EGS developed technology intangible assets over ten years, the trademark intangible assets over 11 years, and the customer list intangible asset on an accelerated basis over 11 years. We have estimated the weighted average life of the intangible assets acquired from EGS to be 10.1 years. The goodwill consists largely of the synergies expected from combining operations and is expected to be deductible for income tax purposes. The pro forma effects to our consolidated results of operations of the EGS Acquisition are not material in relation to reported sales.

On May 17, 2024, Merit Medical Ireland Limited (“MM Ireland”), our indirect wholly-owned subsidiary, entered into a Subscription and Shareholder Agreement (the “CrannMed Agreement”) with CrannMed Limited, a company organized under the laws of Ireland (“CrannMed”). Pursuant to the terms of the CrannMed Agreement, MM Ireland paid €3.0 million to purchase preferred shares of CrannMed. At CrannMed’s election at any time after August 16, 2024, MM Ireland is obligated to pay an additional €3.0 million to acquire additional preferred shares of CrannMed, subject to certain conditions (the “Second Tranche Investment”); no additional amount has been distributed to CrannMed as of September 30, 2024. Additionally, upon the request of CrannMed and subject to the completion of the Second Tranche Investment and other conditions, MM Ireland may pay to CrannMed up to an additional €2.0 million in the form of equity, debt or other investment for the purpose of funding clinical trial activities of CrannMed. MM Ireland’s investment in CrannMed has been recorded as an equity investment accounted for at cost and reflected within other assets in the accompanying consolidated balance sheets because MM Ireland is not able to exercise significant influence over the operations of CrannMed. MM Ireland’s total current investment in CrannMed represented an ownership interest of approximately 10.8% of the outstanding capital stock of CrannMed at the date of the initial purchase.

On March 8, 2024, we entered into an asset purchase agreement with Scholten Surgical Instruments, Inc. (“SSI”) to acquire the assets associated with the Bioptome, Novatome, and Sensatome devices. The total purchase price of the SSI assets included an up-front payment of $3 million, and three deferred payments, including (i) $1 million payable upon the earlier of (a) the first anniversary of the closing date or (b) the date on which Merit can independently manufacture the purchased devices (“Deferred Payment Date”), (ii) $1 million payable upon the first anniversary of the Deferred Payment Date, and (iii) $1 million payable upon the second anniversary of the Deferred Payment Date. We have accounted for this transaction as an asset purchase, and recorded the amount paid and deferred payments as a developed technology intangible asset, which we are amortizing over eight years.

13

Table of Contents

During March 2024, we paid $0.3 million to acquire additional Series A Preferred Stock of Fluidx Medical Technology, Inc. ("Fluidx"), owner of certain technology proposed to be used in the development of embolic and adhesive agents for use in arterial, venous, vascular graft and cardiovascular applications inside and outside the heart and related appendages. We had previously purchased and continue to hold $4.7 million of participating preferred shares of Fluidx. Our investment has been recorded as an equity investment accounted for at cost and reflected within other assets in the accompanying consolidated balance sheets because we are not able to exercise significant influence over the operations of Fluidx. Our total current investment in Fluidx represented an ownership interest of approximately 19.9% of the outstanding capital stock of Fluidx at the date of this investment.

On June 8, 2023, we entered into an asset purchase agreement with AngioDynamics, Inc. (“AngioDynamics”) to acquire the assets associated with a portfolio of dialysis catheter products and the BioSentry® Biopsy Tract Sealant System for a purchase price of $100 million (collectively, the “AngioDynamics Acquisition”). We accounted for the AngioDynamics Acquisition under the acquisition method of accounting as a business combination. The sales related to the AngioDynamics Acquisition have been included in our cardiovascular segment since the acquisition date and were $21.0 million and $8.3 million for the nine-month periods ended September 30, 2024 and 2023, respectively. It is not practical to separately report earnings related to the AngioDynamics Acquisition, as we began to immediately integrate the acquisition into the existing operations, sales distribution networks and management structure of our cardiovascular business segment. Acquisition-related costs associated with the AngioDynamics Acquisition, which were included in selling, general and administrative expenses in the consolidated statements of income included in the 2023 Annual Report on Form 10-K, were approximately $4.9 million. The purchase price was allocated as follows (in thousands):

​

​ | ​ | ​ | ​
Assets Acquired |  | ​ |
Prepaid expenses | ​ | $ | 2,000
Inventories | ​ |  | 5,254
Property and equipment | ​ | ​ | 108
Intangible assets | ​ |  | ​
Developed technology | ​ | ​ | 65,200
Trademarks | ​ | ​ | 4,000
Customer list | ​ | ​ | 5,800
Goodwill | ​ | ​ | 17,638
Total net assets acquired | ​ | $ | 100,000

​

We are amortizing the AngioDynamics developed technology intangible assets over ten years, the trademark intangible assets over 11 years, and the customer list intangible asset on an accelerated basis over ten years. We have estimated the weighted average life of the intangible assets acquired from AngioDynamics to be 10.5 years. The goodwill consists largely of the synergies expected from combining operations and is expected to be deductible for income tax purposes. The pro forma effects to our consolidated results of operations of the AngioDynamics Acquisition are not material in relation to reported sales and it was deemed impracticable to obtain information to determine earnings associated with the acquired product lines which represent only a small portion of the product lines of a large, consolidated company without standalone financial information.

14

Table of Contents

On May 4, 2023, we entered into an asset purchase agreement to acquire the assets associated with the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc. (“Bluegrass”), for a purchase price of $32.7 million. Prior to the acquisition, we held an equity investment of 1,251,878 Bluegrass common shares, representing an approximately 19.5% ownership interest in Bluegrass. The fair value of this previously-held equity investment of approximately $245,000 is included in the purchase price allocation. We accounted for this transaction under the acquisition method of accounting as a business combination. The sales and results of operations related to the acquisition have been included in our cardiovascular segment since the acquisition date and were not material. Acquisition-related costs associated with the Bluegrass acquisition, which were included in selling, general and administrative expenses in the consolidated statements of income included in the 2023 Annual Report on Form 10-K, were not material. The purchase price was allocated as follows (in thousands):

​

​ | ​ | ​ | ​
Assets Acquired |  | ​ |
Inventories | ​ | $ | 175
Intangible assets | ​ |  | ​
Developed technology | ​ | ​ | 28,000
Trademarks | ​ | ​ | 900
Goodwill | ​ | ​ | 3,898
Total net assets acquired | ​ | $ | 32,973

​

We are amortizing the Bluegrass developed technology intangible asset over 15 years and the related trademarks over 13 years. We have estimated the weighted average life of the intangible assets acquired from Bluegrass to be 14.9 years. The goodwill consists largely of the synergies expected from combining operations and is expected to be deductible for income tax purposes. The pro forma effects to our consolidated results of operations of the Bluegrass acquisition are not material.

​

5. Inventories. Inventories at September 30, 2024 and December 31, 2023 consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2024 |  | December 31, 2023
Finished goods | ​ | $ | 159,647 | ​ | $ | 158,893
Work-in-process | ​ |  | 37,694 | ​ |  | 25,420
Raw materials | ​ |  | 113,186 | ​ |  | 119,558
Total inventories | ​ | $ | 310,527 | ​ | $ | 303,871

​

​

​

6. Goodwill and Intangible Assets. The change in the carrying amount of goodwill by segment for the nine-month period ended September 30, 2024 is detailed as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Cardiovascular | ​ | Endoscopy | ​ | Total
Goodwill balance at January 1 | ​ | $ | 382,240 | ​ | $ | — | ​ | $ | 382,240
Effect of foreign exchange | ​ |  | 211 | ​ |  | — | ​ |  | 211
Additions and adjustments as the result of acquisitions | ​ |  | — | ​ |  | 16,997 | ​ |  | 16,997
Goodwill balance at September 30 | ​ | $ | 382,451 | ​ | $ | 16,997 | ​ | $ | 399,448

​

Total accumulated goodwill impairment losses aggregated to $8.3 million as of September 30, 2024 and December 31, 2023, respectively. We did not have any goodwill impairments for the nine-month periods ended September 30, 2024 or 2023.

​

15

Table of Contents

Other intangible assets at September 30, 2024 and December 31, 2023 consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2024
​ | ​ | Gross Carrying | ​ | Accumulated | ​ | Net Carrying
​ |  | Amount |  | Amortization |  | Amount
Patents | ​ | $ | 30,472 | ​ | $ | (12,315) | ​ | $ | 18,157
Distribution agreements | ​ |  | 3,250 | ​ |  | (2,975) | ​ |  | 275
License agreements | ​ |  | 11,599 | ​ |  | (8,979) | ​ |  | 2,620
Trademarks | ​ |  | 40,538 | ​ |  | (23,235) | ​ |  | 17,303
Customer lists | ​ |  | 46,959 | ​ |  | (35,475) | ​ |  | 11,484
Total | ​ | $ | 132,818 | ​ | $ | (82,979) | ​ | $ | 49,839

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2023
​ | ​ | Gross Carrying | ​ | Accumulated | ​ | Net Carrying
​ |  | Amount |  | Amortization |  | Amount
Patents | ​ | $ | 28,877 | ​ | $ | (10,916) | ​ | $ | 17,961
Distribution agreements | ​ |  | 3,250 | ​ |  | (2,919) | ​ |  | 331
License agreements | ​ |  | 11,142 | ​ |  | (8,327) | ​ |  | 2,815
Trademarks | ​ |  | 35,135 | ​ |  | (20,804) | ​ |  | 14,331
Customer lists | ​ |  | 40,367 | ​ |  | (33,921) | ​ |  | 6,446
Total | ​ | $ | 118,771 | ​ | $ | (76,887) | ​ | $ | 41,884

​

Aggregate amortization expense for the three and nine-month periods ended September 30, 2024 was $16.9 million and $46.4 million, respectively. Aggregate amortization expense for the three and nine-month periods ended September 30, 2023 was $15.4 million and $41.1 million, respectively.

​

We evaluate long-lived assets, including amortizing intangible assets, for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We perform the impairment analysis at the asset group for which the lowest level of identifiable cash flows is largely independent of the cash flows of other assets and liabilities. If a triggering event is identified, we determine the fair value of our amortizing assets based on estimated future cash flows discounted back to their present value using a discount rate that reflects the risk profiles of the underlying activities. We did not identify indicators of impairment for our intangible assets based on our consideration of triggering events for the nine-month periods ended September 30, 2024 and 2023, respectively.

​

Estimated amortization expense for developed technology and other intangible assets for the next five years consisted of the following as of September 30, 2024 (in thousands):

​ | ​ | ​ | ​
​ |  | Estimated Amortization Expense
Remaining 2024 | ​ | $ | 17,783
2025 | ​ |  | 69,119
2026 | ​ |  | 58,484
2027 | ​ | ​ | 54,947
2028 | ​ |  | 53,409

​

​

7. Income Taxes. Our provision for income taxes for the three-month periods ended September 30, 2024 and 2023 was a tax expense of $8.2 million and $4.4 million, respectively, which resulted in an effective tax rate of 22.4% and 14.5%, respectively. Our provision for income taxes for the nine-month periods ended September 30, 2024 and 2023 was a tax expense of $24.4 million and $13.8 million, respectively, which resulted in an effective tax rate of 20.9% and 17.2%, respectively. The increase in the effective income tax rate for the three and nine-month periods ended September 30, 2024, when compared to the respective prior-year periods, was primarily due to decreased benefit from discrete items such as share-based compensation and decreased foreign tax credit utilization. The increase in the income tax expense for the nine-month period ended September 30, 2024, when compared to the prior-year period, was primarily due to increased pre-tax book income. Our effective tax rate differs from the U.S. statutory rate primarily due to the impact of global intangible low-taxed income (“GILTI”) inclusions, state income taxes, foreign taxes, other nondeductible permanent items and discrete items (such as share-based compensation).

16

Table of Contents

The Organization for Economic Cooperation and Development (“OECD”) Pillar Two global minimum tax rules, which generally provide for a minimum effective tax rate of 15%, are intended to apply for tax years beginning in 2024. On February 2, 2023, the OECD issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. Under a transitional safe harbor released July 17, 2023, the undertaxed profits rule top-up tax in the jurisdiction of a company's ultimate parent entity will be zero for each fiscal year of the transition period, if that jurisdiction has a corporate tax rate of at least 20%. The safe harbor transition period will apply to fiscal years beginning on or before December 31, 2025 and ending before December 31, 2026. While we expect our effective income tax rate and cash income tax payments could increase in future years as a result of the global minimum tax, we do not anticipate a material impact to our fiscal 2024 consolidated results of operations. Our assessment could be affected by legislative guidance and future enactment of additional provisions within the Pillar Two framework. We are closely monitoring developments and evaluating the impact these new rules are anticipated to have on our tax rate, including eligibility to qualify for these safe harbor rules.

​

8. Debt. Principal balances outstanding under our long-term debt obligations as of September 30, 2024 and December 31, 2023 consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2024 |  | December 31, 2023
Term loans | ​ | $ | 23,000 | ​ | $ | 99,063
Revolving credit loans | ​ |  | — | ​ |  | —
Convertible notes | ​ | ​ | 747,500 | ​ | ​ | 747,500
Less unamortized debt issuance costs | ​ |  | (19,995) | ​ |  | (23,550)
Total long-term debt | ​ |  | 750,505 | ​ |  | 823,013
Less current portion | ​ |  | — | ​ |  | —
Long-term portion | ​ | $ | 750,505 | ​ | $ | 823,013

​

Future minimum principal payments on our long-term debt, as of September 30, 2024, were as follows (in thousands):

​

​ | ​ | ​ | ​
Years Ending | ​ | Future Minimum
December 31, |  | Principal Payments
Remaining 2024 |  | $ | —
2025 | ​ | ​ | —
2026 | ​ | ​ | —
2027 | ​ | ​ | —
2028 | ​ | ​ | 23,000
Thereafter | ​ | ​ | 747,500
Total future minimum principal payments | ​ | $ | 770,500

​

Fourth Amended and Restated Credit Agreement

​

On June 6, 2023, we entered into a Fourth Amended and Restated Credit Agreement (the "Fourth A&R Credit Agreement"). The Fourth A&R Credit Agreement is a syndicated loan agreement with Wells Fargo Bank, National Association and other parties. The Fourth A&R Credit Agreement amended and restated in its entirety our previously outstanding Third Amended and Restated Credit Agreement and all amendments thereto. The Fourth A&R Credit Agreement provides for a term loan of $150 million and a revolving credit commitment of up to an aggregate amount of $700 million, inclusive of sub-facilities for multicurrency borrowings, standby letters of credit and swingline loans. On June 6, 2028, all principal, interest and other amounts outstanding under the Fourth Amended Credit Agreement are payable in full. At any time prior to the maturity date, we may repay any amounts owing under all term loans and revolving credit loans in whole or in part, without premium or penalty.

​

On December 5, 2023, we executed an amendment to the Fourth Amended Credit Agreement (as amended, the "Amended Fourth A&R Credit Agreement") to facilitate the issuance of our Convertible Notes described below. Among other things, the amendment also updated the definition of the “Applicable Margin” as used in the Amended Fourth A&R Credit Agreement to determine the interest rates and amended the financial covenants, all as described below.

17

Table of Contents

​

Term loans made under the Amended Fourth A&R Credit Agreement bear interest, at our election, at either (i) the Base Rate plus the Applicable Margin (as defined in the Amended Fourth A&R Credit Agreement) or, (ii) Adjusted Term SOFR plus the Applicable Margin (as defined in the Amended Fourth A&R Credit Agreement). Revolving credit loans bear interest, at our election, at either (a) the Base Rate plus the Applicable Margin, (b) Adjusted Term SOFR plus the Applicable Margin, (c) Adjusted Eurocurrency Rate plus the Applicable Margin (as defined in the Amended Fourth A&R Credit Agreement), or (d) Adjusted Daily Simple SONIA plus the Applicable Margin (as defined in the Amended Fourth A&R Credit Agreement). Swingline loans bear interest at the Base Rate plus the Applicable Margin. Interest on each loan featuring the Base Rate and each Daily Simple SONIA Loan is due and payable on the last business day of each calendar month; interest on each loan featuring the Eurocurrency Rate and each Term SOFR Loan is due and payable on the last day of each interest period applicable thereto, and if such interest period extends over three months, at the end of each three-month interval during such interest period.

​

The Amended Fourth A&R Credit Agreement is collateralized by substantially all of our assets. The Amended Fourth A&R Credit Agreement contains affirmative and negative covenants, representations and warranties, events of default and other terms customary for loans of this nature. In particular, the Amended Fourth A&R Credit Agreement requires that we maintain certain financial covenants, as follows:

​ | ​ | ​ | ​ | ​
​ |  | Covenant Requirement | ​
Consolidated Total Net Leverage Ratio (1) |  | ​ | 5.0 to 1.0 | ​
Consolidated Senior Secured Net Leverage Ratio (2) | ​ | ​ | 3.0 to 1.0 | ​
Consolidated Interest Coverage Ratio (3) |  | ​ | 3.0 to 1.0 | ​

​

(1) | Maximum Consolidated Total Net Leverage Ratio (as defined in the Amended Fourth A&R Credit Agreement) as of any fiscal quarter end.

(2) | Maximum Consolidated Senior Secured Net Leverage Ratio (as defined in the Amended Fourth A&R Credit Agreement) as of any fiscal quarter end.

(3) | Minimum ratio of Consolidated EBITDA (as defined in the Amended Fourth A&R Credit Agreement and adjusted for certain expenditures) to Consolidated Interest Expense (as defined in the Amended Fourth A&R Credit Agreement) for any period of four consecutive fiscal quarters.

​

We were in compliance with these financial covenants set forth in the Amended Fourth A&R Credit Agreement as of September 30, 2024.

As of September 30, 2024, we had outstanding borrowings of $23.0 million and issued letter of credit guarantees of $2.4 million under the Amended Fourth A&R Credit Agreement, with additional available borrowings of approximately $697 million, based on the maximum net leverage ratio and the aggregate revolving credit commitment pursuant to the Amended Fourth A&R Credit Agreement. Our interest rate as of September 30, 2024 was a variable rate of 6.70% with respect to the outstanding principal amount. Our interest rate as of December 31, 2023 was a fixed rate of 3.39% on $75 million as a result of an interest rate swap and a variable floating rate of 7.21% on $24.1 million. The foregoing interest rates do not reflect potential future changes in the Applicable Margin.

Convertible Notes

In December 2023, we issued convertible notes which bear interest at 3.00% per year, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 (the “Convertible Notes”). The Convertible Notes are senior unsecured obligations (as defined in the indenture governing the Convertible Notes (the “Indenture”)) of Merit and will mature on February 1, 2029, unless repurchased, redeemed or converted in accordance with their terms prior to such date. The net proceeds from the sale of the Convertible Notes were approximately $724.8 million after deducting offering and issuance costs and before the costs of the Capped Call Transactions, as described below.

18

Table of Contents

The initial conversion rate of the notes will be 11.5171 shares of our common stock (the “Common Stock”) per $1,000 principal amount of notes, which equates to an initial conversion price of approximately $86.83 per share of Common Stock, subject to adjustments as provided in the Indenture upon the occurrence of certain specified events. In addition, holders of the Convertible Notes (“Holders”) will have the right to require Merit to repurchase all or a part of their notes upon the occurrence of a “fundamental change” (as defined in the Indenture) in cash at a fundamental change repurchase price of 100% of their principal amount plus accrued and unpaid interest up to, but excluding, the fundamental change repurchase date.

​

Conversion can occur at the option of the Holders at any time on or after October 1, 2028. Prior to October 1, 2028, Holders may only elect to convert the Convertible Notes under the following circumstances: (1) During the five business day period after any ten consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of the Common Stock and the applicable conversion rate on such trading day; (2) Merit issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of Common Stock at a price per share less than the average closing sale price of 10 consecutive trading days, or Merit’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price; (3) Upon the occurrence of a Fundamental Change, as set forth in the Indenture; (4) During any calendar quarter (and only during such calendar quarter) beginning after March 31, 2024, if, the last reported sale price per share of the Common Stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter; or (5) Prior to the related redemption date if Merit calls any Convertible Notes for redemption. As of September 30, 2024, none of the conditions permitting the Holders to convert their Convertible Notes early had been met. Therefore, the Convertible Notes are classified as long-term debt obligations.

​

On or after February 7, 2027, we may redeem for cash all or part of the Convertible Notes, at our option, if the last reported sales price of Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading days ending on, and including, the trading day immediately before the date we send the related notice of the redemption.

​

Upon conversion, Merit will (1) pay cash up to the aggregate principal amount of the Convertible Notes to be converted and (2) pay or deliver, as the case may be, cash, shares of Common Stock, or a combination of cash and shares of Common Stock, at Merit’s election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Convertible Notes being converted.

​

Capped Call Transactions

​

In December 2023, in connection with the pricing of the Convertible Notes, Merit entered into privately negotiated capped call transactions (“Capped Call Transactions”) with certain of the initial purchasers and/or their respective affiliates and certain other financial institutions. The Capped Call Transactions cover, subject to customary anti-dilution adjustments, the number of shares of Common Stock initially underlying the Convertible Notes and are generally expected to reduce potential dilution to the Common Stock upon any conversion of Convertible Notes and/or offset any cash payments Merit is required to make in excess of the principal amount of converted Convertible Notes, as the case may be, with such reduction and/or offset subject to a cap, based on a cap price initially equal to approximately $114.68 per share of Common Stock, subject to certain adjustments under the terms of the Capped Call Transactions. The cost of the Capped Call Transactions was approximately $66.5 million. The Capped Call Transactions do not meet the criteria for separate accounting as a derivative as they are indexed to the Common Stock. The premiums paid for the Capped Call Transactions have been included as a net reduction to Common Stock within stockholders' equity.

​

19

Table of Contents

9. Derivatives.

General. Our earnings and cash flows are subject to fluctuations due to changes in interest rates and foreign currency exchange rates, and we seek to mitigate a portion of the risks attributable to those fluctuations by entering into derivative contracts. The derivative instruments we use are interest rate swaps and foreign currency forward contracts. We recognize derivative instruments as either assets or liabilities at fair value in the accompanying consolidated balance sheets, regardless of whether hedge accounting is applied. We report cash flows arising from our hedging instruments consistent with the classification of cash flows from the underlying hedged items. Accordingly, cash flows associated with our derivative contracts are classified as operating activities in the accompanying consolidated statements of cash flows.

​

We formally document, designate and assess the effectiveness of transactions that receive hedge accounting treatment initially and on an ongoing basis. For qualifying hedges, the change in fair value is deferred in accumulated other comprehensive income, a component of stockholders’ equity in the accompanying consolidated balance sheets, and recognized in earnings at the same time the hedged item affects earnings. Changes in the fair value of derivative instruments not designated as hedging instruments are recorded in earnings throughout the term of the derivative.

​

Interest Rate Risk. Our debt bears interest at variable interest rates. Therefore, we are subject to variability in the cash payable for interest expense. In order to mitigate a portion of the risk attributable to such variability, we use a hedging strategy to reduce the variability of cash flows in the interest payments associated with a portion of the variable-rate debt outstanding under our Amended Fourth A&R Credit Agreement that varies in accordance with changes in the benchmark interest rate.

Derivatives Designated as Cash Flow Hedges

On December 23, 2019, we entered into a pay-fixed, receive-variable interest rate swap with a notional amount of $75 million with Wells Fargo. In June 2023, certain terms under the swap agreement were amended to reflect the transition from LIBOR to SOFR, an alternative reference rate. Under the interest rate swap agreement, we fixed the one-month SOFR rate on that portion of our borrowings under the Amended Fourth A&R Credit Agreement at 1.64% for the period from June 1, 2023 to July 31, 2024. The variable portion of the interest rate swap is tied to the one-month SOFR rate (the benchmark interest rate). On a monthly basis, the interest rates under both the interest rate swap and the underlying debt reset, the swap is settled with the counterparty, and interest is paid.

As of September 30, 2024, the term of our interest rate swap has expired. On December 31, 2023, our interest rate swap qualified as a cash flow hedge. The fair value of our interest rate swap as of December 31, 2023 was an asset of $1.5 million, partially offset by $0.4 million in deferred taxes.

Foreign Currency Risk. We operate on a global basis and are exposed to the risk that our financial condition, results of operations, and cash flows could be adversely affected by changes in foreign currency exchange rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions. Our policy is to enter into foreign currency derivative contracts with maturities of up to two years. We are exposed to foreign currency exchange rate risk with respect to transactions and balances denominated in various currencies, with our most significant exposure related to transactions and balances denominated in Chinese Renminbi and Euros, among others. We do not use derivative financial instruments for trading or speculative purposes. We do not believe we are subject to any credit risk contingent features related to our derivative contracts, and we seek to manage counterparty risk by allocating derivative contracts among several major financial institutions.

20

Table of Contents

Derivatives Designated as Cash Flow Hedges

​

For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative instrument is temporarily reported as a component of other comprehensive income and then reclassified into earnings in the same line item associated with the forecasted transaction and in the same period or periods during which the hedged transaction affects earnings. We entered into forward contracts on various foreign currencies to manage the risk associated with forecasted exchange rates which impact revenues, cost of sales, and operating expenses in various international markets. The objective of the forward contracts is to reduce the variability of cash flows associated with the forecasted purchase or sale of the foreign currencies. As of September 30, 2024 and December 31, 2023, we had entered into foreign currency forward contracts, which qualified as cash flow hedges, with aggregate notional amounts of $155.4 million and $141.1 million, respectively.

Derivatives Not Designated as Cash Flow Hedges

​

We forecast our net exposure in various receivables and payables to fluctuations in the value of various currencies, and we enter into foreign currency forward contracts to mitigate that exposure. As of September 30, 2024 and December 31, 2023, we had entered into foreign currency forward contracts related to those balance sheet accounts with aggregate notional amounts of $115.6 million and $108.4 million, respectively.

Balance Sheet Presentation of Derivative Instruments. As of September 30, 2024 and December 31, 2023, all derivative instruments, both those designated as hedging instruments and those that were not designated as hedging instruments, were recorded at fair value on a gross basis on our consolidated balance sheets. We are not subject to any master netting agreements.

The fair value of derivative instruments on a gross basis was as follows on the dates indicated (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fair Value of Derivative Instruments Designated as Hedging Instruments |  | Balance Sheet Location |  | September 30, 2024 |  | December 31, 2023
Assets |  |  |  | ​ |  |  | ​ |
Interest rate swap |  | Prepaid expenses and other assets | ​ | $ | — | ​ | $ | 1,503
Foreign currency forward contracts |  | Prepaid expenses and other assets | ​ | ​ | 612 | ​ | ​ | 2,061
Foreign currency forward contracts |  | Other assets (long-term) | ​ | ​ | 137 | ​ |  | 216
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(Liabilities) |  |  | ​ |  |  | ​ |  |
Foreign currency forward contracts |  | Accrued expenses | ​ |  | (2,968) | ​ |  | (1,898)
Foreign currency forward contracts |  | Other long-term obligations | ​ |  | (1,085) | ​ |  | (499)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fair Value of Derivative Instruments Not Designated as Hedging Instruments |  | Balance Sheet Location |  | September 30, 2024 |  | December 31, 2023
Assets |  |  | ​ |  |  | ​ |  |
Foreign currency forward contracts |  | Prepaid expenses and other assets | ​ | $ | 685 | ​ | $ | 828
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(Liabilities) |  |  | ​ |  |  | ​ |  |
Foreign currency forward contracts |  | Accrued expenses | ​ |  | (1,753) | ​ |  | (1,463)

​

21

Table of Contents

Income Statement Presentation of Derivative Instruments.

​

Derivative Instruments Designated as Cash Flow Hedges

​

Derivative instruments designated as cash flow hedges had the following effects, before income taxes, on other comprehensive income (“OCI”), accumulated other comprehensive income (“AOCI”), and net earnings in our consolidated statements of income, consolidated statements of comprehensive income and consolidated balance sheets (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Amount of Gain/(Loss) | ​ | ​ | ​ | Consolidated Statements | ​ | Amount of Gain/(Loss)
​ | ​ | Recognized in OCI | ​ | ​ | ​ | of Income | ​ | Reclassified from AOCI
​ | ​ | Three Months Ended September 30, |  | ​ |  | Three Months Ended September 30, | ​ | Three Months Ended September 30,
Derivative instrument |  | 2024 |  | 2023 |  | Location in statements of income |  | 2024 |  |  | 2023 |  | 2024 |  |  | 2023
Interest rate swap | ​ | $ | 1 | ​ | $ | 126 | ​ | Interest expense | ​ | $ | (7,501) | ​ | $ | (4,841) | ​ | $ | 255 | ​ | $ | 685
Foreign currency forward contracts | ​ |  | (5,443) | ​ |  | 1,503 | ​ | Revenue | ​ |  | 339,845 | ​ |  | 315,230 | ​ |  | 709 | ​ |  | 866
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Cost of sales | ​ |  | (182,310) | ​ |  | (173,031) | ​ |  | 179 | ​ |  | 617

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Amount of Gain/(Loss) | ​ | ​ | Consolidated Statements | ​ | Amount of Gain/(Loss) | ​
​ | ​ | Recognized in OCI | ​ | ​ | of Income | ​ | Reclassified from AOCI | ​
​ | ​ | Nine Months Ended September 30, | ​ | ​ | Nine Months Ended September 30, | ​ | Nine Months Ended September 30, |
Derivative instrument |  | 2024 |  | 2023 |  | Location in statements of income |  | 2024 |  | ​ | 2023 |  | 2024 |  |  | 2023 |
Interest rate swap | ​ | $ | 152 | ​ | $ | 726 | ​ | Interest expense | ​ | $ | (23,226) | ​ | $ | (10,534) | ​ | $ | 1,656 | ​ | $ | 1,850 | ​
Foreign currency forward contracts | ​ |  | (1,308) | ​ |  | 6,067 | ​ | Revenue | ​ |  | 1,001,356 | ​ |  | 932,851 | ​ |  | 1,549 | ​ |  | 2,851 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Cost of sales | ​ |  | (531,006) | ​ |  | (499,508) | ​ |  | 963 | ​ |  | 900 | ​

​

As of September 30, 2024, $2.0 million, or $1.5 million after taxes, was expected to be reclassified from AOCI to earnings in revenue and cost of sales over the succeeding twelve months.

Derivative Instruments Not Designated as Hedging Instruments

​

The following gains/(losses) from these derivative instruments were recognized in our consolidated statements of income for the periods presented (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Three Months Ended September 30, |  | Nine Months Ended September 30, |
Derivative Instrument |  | Location in statements of income |  | 2024 |  | 2023 |  | 2024 |  | 2023 |
Foreign currency forward contracts |  | Other income (expense) — net | ​ | $ | (2,124) | ​ | $ | (452) | ​ | $ | (596) | ​ | $ | 2,748 | ​

​

​

22

Table of Contents

10. Commitments and Contingencies.

Litigation. In the ordinary course of business, we are involved in various claims and litigation matters. These proceedings, actions and claims may involve product liability, intellectual property, contract disputes, employment, governmental inquiries or other matters, including the matter described below. These matters generally involve inherent uncertainties and often require prolonged periods of time to resolve. In certain proceedings, the claimants may seek damages, as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which our management had sufficient information to reasonably estimate our future obligations, a liability representing management’s best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect our financial position, results of operations and cash flows. The ultimate cost to us with respect to actions and claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. Unless included in our legal accrual, we are unable to estimate a reasonably possible loss or range of loss associated with any individual material legal proceeding. Legal costs for these matters, such as outside counsel fees and expenses, are charged to expense in the period incurred.

SEC Inquiry

​

We have received requests from the Division of Enforcement of the U.S. Securities and Exchange Commission (“SEC”) seeking the voluntary production of information relating to the business activities of Merit’s subsidiary in China, including interactions with hospitals and health care officials in China (the “SEC Inquiry”). We are cooperating with the requests and investigating the matter. Currently, we are unable to predict the scope, timing, significance or outcome of the SEC Inquiry or estimate a reasonably possible loss or range of loss associated with the matter. It is possible that the ultimate resolution of the SEC Inquiry, if resolved in a manner unfavorable to us, may be materially adverse to our business, financial position, results of operations or liquidity.

​

In management's opinion, based on its examination of these matters, its experience to date and discussions with counsel, other than the SEC Inquiry, we are not currently involved in any legal proceedings which, individually or in the aggregate, could have a material adverse effect on our financial position, results of operations or cash flows. Our management regularly assesses the risks of legal proceedings in which we are involved, and management’s view of these matters may change in the future.

23

Table of Contents

​

11. Earnings Per Common Share (EPS). The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the three and nine-month periods ended September 30, 2024 and 2023 consisted of the following (in thousands, except per share amounts):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ | ​ | 2024 | ​ | 2023 | ​ | 2024 | ​ | 2023 | ​
Net income | ​ | $ | 28,444 | ​ | $ | 25,834 | ​ | $ | 92,410 | ​ | $ | 66,782 | ​
Average common shares outstanding | ​ |  | 58,231 | ​ |  | 57,682 | ​ |  | 58,110 | ​ |  | 57,525 | ​
Basic EPS | ​ | $ | 0.49 | ​ | $ | 0.45 | ​ | $ | 1.59 | ​ | $ | 1.16 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Average common shares outstanding | ​ | ​ | 58,231 | ​ | ​ | 57,682 | ​ | ​ | 58,110 | ​ | ​ | 57,525 | ​
Effect of dilutive stock awards | ​ | ​ | 866 | ​ | ​ | 693 | ​ | ​ | 691 | ​ | ​ | 820 | ​
Effect of dilutive convertible notes | ​ | ​ | 440 | ​ | ​ | — | ​ | ​ | 147 | ​ | ​ | — | ​
Total potential shares outstanding | ​ | ​ | 59,537 | ​ | ​ | 58,375 | ​ | ​ | 58,948 | ​ | ​ | 58,345 | ​
Diluted EPS | ​ | $ | 0.48 | ​ | $ | 0.44 | ​ | $ | 1.57 | ​ | $ | 1.14 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Equity awards excluded as the impact was anti-dilutive (1) | ​ | ​ | 448 | ​ | ​ | 1,242 | ​ | ​ | 821 | ​ | ​ | 1,091 | ​

(1) | Does not reflect the impact of incremental repurchases under the treasury stock method.

​

Convertible Notes

​

For our Convertible Notes, the dilutive effect is calculated using the if-converted method. Upon surrender of the Convertible Notes for conversion, Merit will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of Common Stock or a combination of cash and shares of Common Stock, at Merit’s election, in respect of the remainder, if any, of Merit’s conversion obligation in excess of the aggregate principal amount of the Convertible Notes being converted. Under the if-converted method, we include the number of shares required to satisfy the remaining conversion obligation, assuming all the Convertible Notes were converted. The convertible notes only have an impact on diluted earnings per share when the average share price of our common stock exceeds the conversion price of $86.83. The average closing price of the Common Stock for the period ended September 30, 2024 was used as the basis for determining the dilutive effect on EPS.

​

​

12. Stock-Based Compensation Expense. Stock-based compensation expense before income tax expense for the three and nine-month periods ended September 30, 2024 and 2023 consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2024 |  | 2023 |  | 2024 |  | 2023
Cost of sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nonqualified stock options | ​ | $ | 150 | ​ | $ | 367 | ​ | $ | 875 | ​ | $ | 1,240
Research and development | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Nonqualified stock options | ​ | ​ | 440 | ​ |  | 488 | ​ | ​ | 1,221 | ​ |  | 1,329
Selling, general and administrative | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Nonqualified stock options | ​ | ​ | 1,442 | ​ |  | 2,083 | ​ | ​ | 4,689 | ​ |  | 5,304
Performance-based restricted stock units | ​ | ​ | 2,884 | ​ | ​ | 1,838 | ​ | ​ | 7,648 | ​ | ​ | 4,470
Restricted stock units | ​ | ​ | 1,074 | ​ | ​ | 430 | ​ | ​ | 2,792 | ​ | ​ | 1,341
Cash-settled performance-based awards | ​ | ​ | 723 | ​ | ​ | 591 | ​ | ​ | 1,733 | ​ | ​ | 1,662
Total selling, general and administrative | ​ | ​ | 6,123 | ​ | ​ | 4,942 | ​ | ​ | 16,862 | ​ | ​ | 12,777
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Stock-based compensation expense before taxes | ​ | $ | 6,713 | ​ | $ | 5,797 | ​ | $ | 18,958 | ​ | $ | 15,346

​

24

Table of Contents

We recognize stock-based compensation expense (net of a forfeiture rate), for those awards which are expected to vest, on a straight-line basis over the requisite service period. We estimate the forfeiture rate based on our historical experience and expectations about future forfeitures.

​

Nonqualified Stock Options

During the nine-month period ended September 30, 2023, we granted stock options representing 401,535 shares of our Common Stock. We did not grant any stock options during the nine-month period ended September 30, 2024. We use the Black-Scholes methodology to value the stock-based compensation expense for options. In applying the Black-Scholes methodology to the option grants, the fair value of our stock-based awards granted was estimated using the following assumptions for the periods indicated below:

​

​ | ​
​ | Nine Months Ended
​ | September 30,
​ | 2023
Risk-free interest rate | 3.6% - 4.6%
Expected option term | 4.0 years
Expected dividend yield | —
Expected price volatility | 44.6% - 47.1%

​

The average risk-free interest rate is determined using the U.S. Treasury rate in effect as of the date of grant, based on the expected term of the stock award. We determine the expected term of stock options using the historical exercise behavior of employees. The expected price volatility was determined using a weighted average of daily historical volatility of our stock price over the corresponding expected option term and implied volatility based on recent trends of the daily historical volatility. For awards with a vesting period, compensation expense is recognized on a straight-line basis over the service period, which corresponds to the vesting period.

​

As of September 30, 2024, the total remaining unrecognized compensation cost related to non-vested stock options was $13.2 million, which was expected to be recognized over a weighted average period of 1.9 years.

​

Stock-Settled Performance-Based Restricted Stock Units (“Performance Stock Units”)

​

During the nine-month periods ended September 30, 2024 and 2023, we granted performance stock units which represented up to 364,810 and 286,863 shares of Common Stock, respectively. Conversion of the performance stock units occurs at the end of the relevant performance periods, or one year after the agreement date, whichever is later. The number of shares delivered upon vesting at the end of the performance periods are based upon performance against specified financial performance metrics and relative total shareholder return as compared to the Russell 2000 Index (“rTSR”), as defined in the award agreements.

​

We use Monte-Carlo simulations to estimate the grant-date fair value of the performance stock units linked to total shareholder return. The fair value of each performance stock unit was estimated as of the grant date using the following assumptions for awards granted in the periods indicated below:

​

​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended
​ | ​ | September 30,
​ | ​ | 2024 | ​ | 2023
Risk-free interest rate |  | 4.4% |  | 3.9% - 4.6%
Performance period |  | 2.8 years |  | 2.8 years
Expected dividend yield |  | — |  | —
Expected price volatility |  | 31.1% |  | 31.4% - 32.6%

​

The risk-free interest rate of return was determined using the U.S. Treasury rate at the time of grant with a term equal to the expected term of the award. The expected volatility was based on the weighted average volatility of our stock price and the average volatility of our compensation peer group's stock price. The expected dividend yield was assumed to be zero because, at the time of the grant, we had no plans to declare a dividend.

25

Table of Contents

Compensation expense is recognized using the grant-date fair value for the number of shares that are likely to be awarded based on the performance metrics. Each reporting period, this probability assessment is updated, and cumulative adjustments are recorded based on the financial performance metrics expected to be achieved. At the end of the performance period, cumulative expense is calculated based on the actual performance metrics achieved. As of September 30, 2024, the total remaining unrecognized compensation cost related to stock-settled performance stock units was $17.5 million, which is expected to be recognized over a weighted average period of 1.9 years.

Cash-Settled Performance-Based Awards

During the nine-month periods ended September 30, 2024 and 2023, we granted performance stock units to our Chief Executive Officer that provide for settlement in cash upon achievement of specific metrics (“Liability Awards”), with total target cash incentives in the amount of $1.6 million and $1.3 million, respectively. The Liability Awards entitle him to a target cash payment based upon our level of rTSR performance and achievement of other performance metrics, as defined in the award agreements.

During the nine-month periods ended September 30, 2024 and 2023, we granted additional performance stock units to certain employees that provide for settlement in cash upon our achievement of specified financial metrics. The cash payable upon vesting at the end of the service period is based upon performance against specified financial performance metrics and relative total shareholder return as compared to the rTSR, as defined in the award agreements. Compensation expense is recognized for the cash payment likely to be awarded based on the performance metrics.

The potential maximum payout of these Liability Awards is 250% of the target cash incentive, resulting in a total potential maximum payout of $4.4 million and $4.6 million for Liability Awards granted during the nine-month periods ended September 30, 2024 and 2023, respectively. The settlement generally occurs at the end of three-year performance periods based upon the same performance metrics and vesting period as our performance stock units.

The fair value of these Liability Awards is measured at each reporting period until the awards are settled. As of September 30, 2024 and December 31, 2023, the recorded balance associated with these Liability Awards is $4.1 million and $3.4 million, respectively, which are classified as liabilities and reported in accrued expenses and other long-term obligations within our consolidated balance sheets. As of September 30, 2024, the total remaining unrecognized compensation cost related to Liability Awards was $3.8 million, which is expected to be recognized over a weighted average period of 1.8 years.

​

Restricted Stock Units

During the nine-month periods ended September 30, 2024 and 2023, we granted restricted stock units to certain employees and non-employee directors representing 158,719 and 20,358 shares of Common Stock, respectively. The expense recognized for restricted stock units is equal to the closing stock price on the date of grant, which is recognized over the vesting period. Restricted stock units granted to each employee are subject to such employee’s continued employment through the vesting date, which is four years from the date of grant. Restricted stock units granted to each non-employee director are subject to such director’s continued service through the vesting date, which is one year from the grant date. As of September 30, 2024, the total remaining unrecognized compensation cost related to restricted stock units was $9.1 million, which will be recognized over a weighted average period of 3.1 years.

​

​

13. Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures. Our chief operating decision maker is our Chief Executive Officer. We evaluate the performance of our operating segments based on net sales and income from operations.

26

Table of Contents

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and nine-month periods ended September 30, 2024 and 2023, were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended |  | Nine Months Ended
​ |  | September 30, |  | September 30,
​ |  | 2024 |  | 2023 |  | 2024 |  | 2023
Net sales |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Cardiovascular | ​ | $ | 322,855 | ​ | $ | 306,084 | ​ | $ | 964,044 | ​ | $ | 905,335
Endoscopy | ​ |  | 16,990 | ​ |  | 9,146 | ​ |  | 37,312 | ​ |  | 27,516
Total net sales | ​ |  | 339,845 | ​ |  | 315,230 | ​ |  | 1,001,356 | ​ |  | 932,851
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income from operations | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Cardiovascular | ​ |  | 37,555 | ​ |  | 32,622 | ​ |  | 113,374 | ​ |  | 82,966
Endoscopy | ​ |  | (294) | ​ |  | 2,515 | ​ |  | 5,755 | ​ |  | 7,366
Total income from operations | ​ |  | 37,261 | ​ |  | 35,137 | ​ |  | 119,129 | ​ |  | 90,332
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total other expense — net | ​ |  | (604) | ​ |  | (4,915) | ​ |  | (2,281) | ​ |  | (9,710)
Income tax expense | ​ |  | 8,213 | ​ |  | 4,388 | ​ |  | 24,438 | ​ |  | 13,840
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 28,444 | ​ | $ | 25,834 | ​ | $ | 92,410 | ​ | $ | 66,782

​

​

​

14. Fair Value Measurements.

Assets (Liabilities) Measured at Fair Value on a Recurring Basis

Our financial assets and (liabilities) carried at fair value and measured on a recurring basis as of September 30, 2024 and December 31, 2023 consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Fair Value Measurements Using
​ | ​ | Total Fair | ​ | Quoted prices in | ​ | Significant other | ​ | Significant
​ | ​ | Value at | ​ | active markets | ​ | observable inputs | ​ | unobservable inputs
​ |  | September 30, 2024 |  | (Level 1) |  | (Level 2) |  | (Level 3)
Marketable securities (1) | ​ | $ | 78 | ​ | $ | 78 | ​ | $ | — | ​ | $ | —
Foreign currency contract assets, current and long-term (3) | ​ | $ | 1,434 | ​ | $ | — | ​ | $ | 1,434 | ​ | $ | —
Foreign currency contract liabilities, current and long-term (4) | ​ | $ | (5,806) | ​ | $ | — | ​ | $ | (5,806) | ​ | $ | —
Contingent consideration liabilities | ​ | $ | (3,419) | ​ | $ | — | ​ | $ | — | ​ | $ | (3,419)

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Fair Value Measurements Using
​ | ​ | Total Fair | ​ | Quoted prices in | ​ | Significant other | ​ | Significant
​ | ​ | Value at | ​ | active markets | ​ | observable inputs | ​ | unobservable inputs
​ |  | December 31, 2023 |  | (Level 1) |  | (Level 2) |  | (Level 3)
Marketable securities (1) | ​ | $ | 78 | ​ | $ | 78 | ​ | $ | — | ​ | ​ | —
Interest rate contract asset, current (2) | ​ | $ | 1,503 | ​ | $ | — | ​ | $ | 1,503 | ​ | $ | —
Foreign currency contract assets, current and long-term (3) | ​ | $ | 3,105 | ​ | $ | — | ​ | $ | 3,105 | ​ | $ | —
Foreign currency contract liabilities, current and long-term (4) | ​ | $ | (3,860) | ​ | $ | — | ​ | $ | (3,860) | ​ | $ | —
Contingent consideration liabilities | ​ | $ | (3,447) | ​ | $ | — | ​ | $ | — | ​ | $ | (3,447)

​

(1) | Our marketable securities, which consist entirely of available-for-sale equity securities, are valued using market prices in active markets. Level 1 instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.

27

Table of Contents

(2) | The fair value of the interest rate contract is determined using Level 2 fair value inputs and is recorded as prepaid and other current assets in the consolidated balance sheets.

(3) | The fair value of the foreign currency contract assets (including those designated as hedging instruments and those not designated as hedging instruments) is determined using Level 2 fair value inputs and is recorded as a prepaid expense and other current asset or other long-term asset in the consolidated balance sheets.

(4) | The fair value of the foreign currency contract liabilities (including those designated as hedging instruments and those not designated as hedging instruments) is determined using Level 2 fair value inputs and is recorded as accrued expense or other long-term obligation in the consolidated balance sheets.

​

Certain of our past business combinations involve the potential for the payment of future contingent consideration, generally based on a percentage of future product sales or upon attaining specified future revenue or other milestones. The contingent consideration liability is re-measured at the estimated fair value at the end of each reporting period with the change in fair value recognized within operating expenses in the accompanying consolidated statements of income for such period. We measure the initial liability and re-measure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. Changes in the fair value of our contingent consideration liabilities during the three and nine-month periods ended September 30, 2024 and 2023 consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended |  | Nine Months Ended
​ |  | September 30, |  | September 30,
​ |  | 2024 |  | 2023 |  | 2024 |  | 2023
Beginning balance | ​ | $ | 3,435 | ​ | $ | 3,581 | ​ | $ | 3,447 | ​ | $ | 18,073
Contingent consideration expense | ​ |  | 103 | ​ |  | 563 | ​ |  | 292 | ​ |  | 2,177
Contingent payments made | ​ |  | (119) | ​ |  | (122) | ​ |  | (320) | ​ |  | (16,228)
Ending balance | ​ | $ | 3,419 | ​ | $ | 4,022 | ​ | $ | 3,419 | ​ | $ | 4,022

​

As of September 30, 2024, $3.0 million in contingent consideration liability was included in other long-term obligations and $0.4 million in contingent consideration liability was included in accrued expenses in our consolidated balance sheet. As of December 31, 2023, $3.0 million in contingent consideration liability was included in other long-term obligations and $0.4 million in contingent consideration liability was included in accrued expenses in our consolidated balance sheet.

Payments related to the settlement of the contingent consideration liability recognized at fair value as of the applicable acquisition date of $0.2 million and $3.5 million for the nine-month periods ended September 30, 2024 and 2023, respectively, have been reflected as a cash outflow from financing activities in the accompanying consolidated statements of cash flows. Payments related to increases in the contingent consideration liability subsequent to the date of acquisition of $0.1 million and $12.7 million for the nine-month periods ended September 30, 2024 and 2023, respectively, are reflected as operating cash flows.

28

Table of Contents

The recurring Level 3 measurement of our contingent consideration liabilities included the following significant unobservable inputs at September 30, 2024 and December 31, 2023 (amounts in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair value at | ​ | ​ | ​ | ​ | ​ | ​ |  | ​
​ | ​ | September 30, | ​ | Valuation | ​ | ​ | ​ | ​ | ​ | Weighted
Contingent consideration liability |  | 2024 |  | technique |  | Unobservable inputs |  | Range | ​ | Average(1)
Revenue-based royalty payments contingent liability | ​ | $ | 2,897 |  | Discounted cash flow |  | Discount rate | ​ | 11% - 15% | ​ | 14.4%
​ | ​ |  |  |  | ​ |  | Projected year of payments | ​ | 2024-2034 | ​ | 2028
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue milestones contingent liability | ​ | $ | 98 |  | Monte Carlo simulation |  | Discount rate | ​ | 12.0% | ​ | ​
​ | ​ |  |  |  | ​ |  | Projected year of payments | ​ | 2024-2040 | ​ | 2040
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Regulatory approval contingent liability | ​ | $ | 424 | ​ | Scenario-based method | ​ | Discount rate | ​ | 5.4% | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Probability of milestone payment | ​ | 50.0% | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Projected year of payment | ​ | 2024-2030 | ​ | 2030

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair value at | ​ | ​ | ​ | ​ | ​ | ​ |  | ​
​ | ​ | December 31, | ​ | Valuation | ​ | ​ | ​ | ​ | ​ | Weighted
Contingent consideration liability |  | 2023 |  | technique |  | Unobservable inputs |  | Range | ​ | Average(1)
Revenue-based royalty payments contingent liability | ​ | $ | 2,945 |  | Discounted cash flow |  | Discount rate | ​ | 12.0% - 16.0% | ​ | 14.6%
​ | ​ |  |  |  | ​ |  | Projected year of payments | ​ | 2024-2034 | ​ | 2028
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue milestones contingent liability | ​ | $ | 93 |  | Monte Carlo simulation |  | Discount rate | ​ | 13.0% | ​ | ​
​ | ​ |  |  |  | ​ |  | Projected year of payments | ​ | 2024-2039 | ​ | 2039
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Regulatory approval contingent liability | ​ | $ | 409 | ​ | Scenario-based method | ​ | Discount rate | ​ | 5.5% | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Probability of milestone payment | ​ | 50.0% | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Projected year of payment | ​ | 2024-2030 | ​ | 2030

(1) | Unobservable inputs were weighted by the relative fair value of the instruments. No weighted average is reported for contingent consideration liabilities without a range of unobservable inputs.

​

The contingent consideration liability is re-measured to fair value each reporting period. Significant increases or decreases in projected revenues, based on our most recent internal operational budgets and long-range strategic plans, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement. Our determination of the fair value of the contingent consideration liability could change in future periods based upon our ongoing evaluation of these significant unobservable inputs. We intend to record any such change in fair value to operating expenses in our consolidated statements of income.

29

Table of Contents

Fair Value of Other Assets (Liabilities)

​

The carrying amount of cash and cash equivalents, receivables, and trade payables approximate fair value because of the immediate, short-term maturity of these financial instruments. Our long-term debt under our Amended Fourth A&R Credit Agreement re-prices frequently due to variable rates and entails no significant changes in credit risk and, as a result, we believe the fair value of long-term debt approximates carrying value. We believe the fair value our long-term debt under our Convertible Notes approximates carrying value as the notes were issued in December 2023. The fair value of assets and liabilities whose carrying value approximates fair value is determined using Level 2 inputs, with the exception of cash and cash equivalents, which use Level 1 inputs.

​

We recognize or disclose the fair value of certain assets, such as non-financial assets, primarily property and equipment, right-of-use operating lease assets, equity investments, intangible assets and goodwill in connection with impairment evaluations. Such assets are reported at carrying value and are not subject to recurring fair value measurements. We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Fair value is generally determined based on discounted future cash flow. All our nonrecurring valuations use significant unobservable inputs and therefore fall under Level 3 of the fair value hierarchy.

​

Our equity investments in privately-held companies were $22.6 million and $19.1 million at September 30, 2024 and December 31, 2023, respectively, which are included within other long-term assets in our consolidated balance sheets. We analyze our investments in privately-held companies to determine if they should be accounted for using the equity method based on our ability to exercise significant influence over operating and financial policies of the investment. Investments not accounted for under the equity method of accounting are accounted for at cost minus impairment, if applicable, plus or minus changes in valuation resulting from observable transactions for identical or similar investments. During the nine-month period ended September 30, 2023, we recorded impairment charges of $0.3 million associated with our previously-held equity investment in Bluegrass in connection with the asset acquisition completed on May 4, 2023 (see Note 4). During the nine-month period ended September 30, 2024, we recorded no impairment charges related to our equity investments.

​

Current Expected Credit Losses

​

Our outstanding long-term notes receivable, including accrued interest and an allowance for current expected credit losses, were $9.3 million and $3.2 million as of September 30, 2024 and December 31, 2023, respectively. Long-term notes receivable issued were $6.7 million for the nine-month period ended September 30, 2024 and were related to loans issued to Selio Medical Limited (“Selio”) of $1.7 million, Solo Pace Inc. (“Solo Pace”) of $2.0 million and Fluidx of $3.0 million. As of September 30, 2024 and December 31, 2023, we had an allowance for current expected credit losses of $1.6 million and $0.6 million, respectively, associated with these notes receivable. We assess the allowance for current expected credit losses on an individual security basis, due to the limited number of securities, using a probability of default model, which is based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the expected collectability of securities, and other security specific factors.

​

The table below presents a roll-forward of the allowance for current expected credit losses on our notes receivable for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ | ​ | 2024 |  | 2023 | ​ | 2024 |  | 2023
Beginning balance | ​ | $ | 1,406 | ​ | $ | 296 | ​ | $ | 568 | ​ | $ | 281
Provision for credit loss expense | ​ | ​ | 189 | ​ | ​ | 32 | ​ | ​ | 1,027 | ​ | ​ | 47
Ending balance | ​ | $ | 1,595 | ​ | $ | 328 | ​ | $ | 1,595 | ​ | $ | 328

​

​

30

Table of Contents

15. Accumulated Other Comprehensive Income (Loss). The changes in each component of accumulated other comprehensive income (loss) for the three and nine-month periods ended September 30, 2024 and 2023 were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Cash Flow Hedges |  | Foreign Currency Translation |  | Total
Balance as of July 1, 2024 | $ | 2,625 | ​ | $ | (18,054) | ​ | $ | (15,429)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other comprehensive income (loss) |  | (5,442) | ​ | ​ | 7,153 | ​ | ​ | 1,711
Income taxes |  | 1,555 | ​ | ​ | (89) | ​ | ​ | 1,466
Reclassifications to: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue | ​ | (709) | ​ | ​ | ​ | ​ | ​ | (709)
Cost of sales | ​ | (179) | ​ | ​ | ​ | ​ | ​ | (179)
Interest expense | ​ | (255) | ​ | ​ | ​ | ​ | ​ | (255)
Net other comprehensive income (loss) | ​ | (5,030) | ​ | ​ | 7,064 | ​ | ​ | 2,034
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of September 30, 2024 | $ | (2,405) | ​ | $ | (10,990) | ​ | $ | (13,395)

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Cash Flow Hedges |  | Foreign Currency Translation |  | Total
Balance as of July 1, 2023 | $ | 5,682 | ​ | $ | (15,226) | ​ | $ | (9,544)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other comprehensive income (loss) |  | 1,629 | ​ | ​ | (2,914) | ​ | ​ | (1,285)
Income taxes |  | 129 | ​ | ​ | 17 | ​ | ​ | 146
Reclassifications to: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue | ​ | (866) | ​ | ​ | ​ | ​ | ​ | (866)
Cost of sales | ​ | (617) | ​ | ​ | ​ | ​ | ​ | (617)
Interest expense | ​ | (685) | ​ | ​ | ​ | ​ | ​ | (685)
Net other comprehensive loss | ​ | (410) | ​ | ​ | (2,897) | ​ | ​ | (3,307)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of September 30, 2023 | $ | 5,272 | ​ | $ | (18,123) | ​ | $ | (12,851)

​

​

31

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Cash Flow Hedges |  | Foreign Currency Translation |  | Total
Balance as of January 1, 2024 | $ | 1,662 | ​ | $ | (12,996) | ​ | $ | (11,334)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other comprehensive income (loss) |  | (1,156) | ​ | ​ | 2,061 | ​ | ​ | 905
Income taxes |  | 1,257 | ​ | ​ | (55) | ​ | ​ | 1,202
Reclassifications to: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue | ​ | (1,549) | ​ | ​ | ​ | ​ | ​ | (1,549)
Cost of sales | ​ | (963) | ​ | ​ | ​ | ​ | ​ | (963)
Interest expense | ​ | (1,656) | ​ | ​ | ​ | ​ | ​ | (1,656)
Net other comprehensive income (loss) | ​ | (4,067) | ​ | ​ | 2,006 | ​ | ​ | (2,061)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of September 30, 2024 | $ | (2,405) | ​ | $ | (10,990) | ​ | $ | (13,395)

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Cash Flow Hedges |  | Foreign Currency Translation |  | Total
Balance as of January 1, 2023 | $ | 4,366 | ​ | $ | (15,916) | ​ | $ | (11,550)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other comprehensive income (loss) |  | 6,793 | ​ | ​ | (2,190) | ​ | ​ | 4,603
Income taxes |  | (286) | ​ | ​ | (17) | ​ | ​ | (303)
Reclassifications to: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue | ​ | (2,851) | ​ | ​ | ​ | ​ | ​ | (2,851)
Cost of sales | ​ | (900) | ​ | ​ | ​ | ​ | ​ | (900)
Interest expense | ​ | (1,850) | ​ | ​ | ​ | ​ | ​ | (1,850)
Net other comprehensive income (loss) | ​ | 906 | ​ | ​ | (2,207) | ​ | ​ | (1,301)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of September 30, 2023 | $ | 5,272 | ​ | $ | (18,123) | ​ | $ | (12,851)

​

​

​

​

16. Subsequent Events. On September 16, 2024, we entered into an Asset Purchase Agreement (the “Cook Purchase Agreement”) with Cook Medical Holdings LLC, an Indiana limited liability company (“Cook Medical”), to purchase Cook Medical’s lead management portfolio of medical devices and certain related assets for total cash consideration of approximately $210 million (collectively, the “Cook Acquisition”). The closing of the proposed Cook Acquisition is expected to occur during the fourth quarter of 2024, subject to the receipt or waiver (in accordance with the provisions of the Cook Purchase Agreement) of certain closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary closing conditions. We expect to fund the Cook Acquisition through a combination of cash on hand and borrowings under our long-term credit facility. In connection with the projected closing of the Cook Acquisition, we propose to enter into a transition services agreement with Cook Medical, pursuant to which Cook Medical would provide manufacturing and other services to us during a two-year transition period. We are currently evaluating the accounting treatment of the Cook Acquisition, as well as performing the valuation of the assets acquired and the related purchase price allocation.

​

​

​

​

32

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related condensed notes thereto, which are included in Part I of this report. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties that may adversely impact our operations and financial results. These risks and uncertainties are discussed in Part I, Item 1A “Risk Factors” in the 2023 Annual Report on Form 10-K and in Part II, Item 1A “Risk Factors” in this report.

​

OVERVIEW

We are a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures.

​

For the three-month period ended September 30, 2024, we reported sales of $339.8 million, an increase of $24.6 million or 7.8% compared to sales for the three-month period ended September 30, 2023 of $315.2 million. For the nine-month period ended September 30, 2024, we reported sales of $1,001.4 million, an increase of $68.5 million or 7.3% compared to sales for the nine-month period ended September 30, 2023 of $932.9 million. Foreign currency fluctuations (net of hedging) decreased our net sales by ($0.3) million and ($5.0) million, respectively, for the three and nine-month periods ended September 30, 2024, assuming applicable foreign exchange rates in effect during the comparable prior-year periods.

​

Gross profit as a percentage of sales increased to 46.4% for the three-month period ended September 30, 2024 compared to 45.1% for the three-month period ended September 30, 2023. Gross profit as a percentage of sales increased to 47.0% for the nine-month period ended September 30, 2024 compared to 46.5% for the nine-month period ended September 30, 2023.

​

Net income for the three-month period ended September 30, 2024 was $28.4 million, or $0.48 per share, compared to net income of $25.8 million, or $0.44 per share, for the three-month period ended September 30, 2023. Net income for the nine-month period ended September 30, 2024 was $92.4 million, or $1.57 per share, compared to net income of $66.8 million, or $1.14 per share, for the nine-month period ended September 30, 2023.

Recent Developments and Trends

In addition to the trends identified in the 2023 Annual Report on Form 10-K under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Overview,” our business in 2024 has been impacted, and we believe will continue to be impacted, by the following recent developments and trends:

| ● | Our revenue results during the three-month period ended September 30, 2024 were driven primarily by demand in the U.S. and favorable international sales trends, particularly in our Europe, Middle East and Africa (“EMEA”) and Asia Pacific (“APAC”) regions.

| ● | On February 28, 2024, we introduced our “Continued Growth Initiatives” Program and related financial targets for the three-year period ending December 31, 2026, which reflects our commitment to better-position Merit for long-term, sustainable growth and enhanced profitability.

| ● | On July 1, 2024, we completed the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux disease.

33

Table of Contents

| ● | We entered into an asset purchase agreement for the acquisition of the lead management portfolio of medical devices and certain related asset from Cook Medical Holdings LLC; closing of the acquisition is expected to occur on November 1, 2024.

| ● | As of September 30, 2024, we had cash, cash equivalents, and restricted cash of $525.3 million and net available borrowing capacity under our Fourth A&R Credit Agreement of approximately $697 million.

​

RESULTS OF OPERATIONS

The following table sets forth certain operational data as a percentage of sales for the periods indicated:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended | ​ | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | ​ | September 30, | ​
​ |  | 2024 |  | 2023 |  |  | 2024 |  | 2023 |
Net sales |  | 100 | % | 100 | % |  | 100 | % | 100 | %
Gross profit |  | 46.4 |  | 45.1 |  |  | 47.0 | ​ | 46.5 |
Selling, general and administrative expenses |  | 29.3 |  | 27.6 |  |  | 28.8 | ​ | 29.8 |
Research and development expenses |  | 6.0 |  | 6.2 |  |  | 6.2 | ​ | 6.5 |
Impairment charges |  | — |  | — |  |  | — | ​ | 0.0 |
Contingent consideration expense |  | 0.0 |  | 0.2 |  |  | 0.0 | ​ | 0.2 |
Acquired in-process research and development expense |  | — |  | — | ​ |  | — | ​ | 0.2 |
Income from operations |  | 11.0 |  | 11.1 |  |  | 11.9 | ​ | 9.7 |
Other expense — net |  | (0.2) |  | (1.6) |  |  | (0.2) | ​ | (1.0) |
Income before income taxes |  | 10.8 |  | 9.6 |  |  | 11.7 | ​ | 8.6 |
Net income |  | 8.4 |  | 8.2 |  |  | 9.2 | ​ | 7.2 |

​

Sales

Sales for the three-month period ended September 30, 2024 increased by 7.8%, or $24.6 million, compared to the corresponding period in 2023. Sales for the nine-month period ended September 30, 2024 increased by 7.3%, or $68.5 million, compared to the corresponding period in 2023. Listed below are the sales by product category within each of our financial reporting segments for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands, other than percentage changes):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ | ​ | Three Months Ended | ​ | ​ | ​ | ​ | Nine Months Ended
​ |  | ​ | ​ | ​ | September 30, | ​ | ​ | ​ | ​ | September 30,
​ |  | % Change |  | ​ | 2024 |  | 2023 |  | % Change |  | ​ | 2024 |  | 2023
Cardiovascular | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Peripheral Intervention |  | 7.4 | % | ​ | $ | 137,932 | ​ | $ | 128,385 | ​ | 11.9 | % | ​ | $ | 411,805 | ​ | $ | 368,077
Cardiac Intervention |  | 1.9 | % | ​ |  | 90,769 | ​ |  | 89,106 |  | 2.7 | % | ​ | ​ | 275,320 | ​ |  | 268,209
Custom Procedural Solutions |  | 4.4 | % | ​ |  | 50,768 | ​ |  | 48,624 |  | 2.9 | % | ​ | ​ | 149,978 | ​ |  | 145,709
OEM |  | 8.5 | % | ​ |  | 43,386 | ​ |  | 39,969 |  | 2.9 | % | ​ | ​ | 126,941 | ​ |  | 123,340
Total |  | 5.5 | % | ​ |  | 322,855 | ​ |  | 306,084 |  | 6.5 | % | ​ | ​ | 964,044 | ​ |  | 905,335
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Endoscopy | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Endoscopy Devices |  | 85.8 | % | ​ |  | 16,990 | ​ |  | 9,146 |  | 35.6 | % | ​ | ​ | 37,312 | ​ |  | 27,516
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total |  | 7.8 | % | ​ | $ | 339,845 | ​ | $ | 315,230 | ​ | 7.3 | % | ​ | $ | 1,001,356 | ​ | $ | 932,851

​

Cardiovascular Sales. Our cardiovascular sales for the three-month period ended September 30, 2024 were $322.9 million, up 5.5% when compared to the corresponding period of 2023 of $306.1 million. Sales for the three-month period ended September 30, 2024 were favorably affected by increased sales of:

34

Table of Contents

| (a) | Peripheral intervention products, which increased by $9.5 million, or 7.4%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our radar localization, drainage, access, and delivery systems products.

| (b) | Cardiac intervention products, which increased by $1.7 million, or 1.9%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our cardiac rhythm management/electrophysiology (“CRM/EP”) and fluid management products, offset partially by decreased sales of our intervention and hemostasis products.

| (c) | Custom procedural solutions products, which increased by $2.1 million, or 4.4%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our critical care products.

| (d) | OEM products, which increased by $3.4 million, or 8.5%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our kits and access, vertebral compression fracture, and fluid management products, offset partially by decreased sales of our CRM/EP, intervention and angiography products.

Our cardiovascular sales for the nine-month period ended September 30, 2024 were $964.0 million, up 6.5% when compared to the corresponding period of 2023 of $905.3 million. Sales for the nine-month period ended September 30, 2024 were favorably affected by increased sales of:

| (a) | Peripheral intervention products, which increased by $43.7 million, or 11.9%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our access, radar localization, drainage, delivery systems, and biopsy products.

| (b) | Cardiac intervention products, which increased by $7.1 million, or 2.7%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our CRM/EP and fluid management products, offset partially by decreased sales of our hemostasis products.

| (c) | Custom procedural solutions products, which increased by $4.3 million, or 2.9%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our kits and critical care products, offset partially by decreased sales of our procedure trays.

| (d) | OEM products, which increased by $3.6 million, or 2.9%, from the corresponding period of 2023. This increase was driven primarily by increased sales of our kits and access, vertebral compression fracture, and fluid management products, offset partially by decreased sales of our CRM/EP and intervention products.

Endoscopy Sales. Our endoscopy sales for the three-month period ended September 30, 2024 were $17.0 million, up 85.8% when compared to sales in the corresponding period of 2023 of $9.1 million. Sales for the three-month period ended September 30, 2024 compared to the corresponding period in 2023 were favorably affected by $6.8 million in sales of the EsophyX® Z+ device acquired from EGS in July 2024 as well as increased sales of our EndoMAXX fully covered esophageal stent and ReSolve Thoracostomy Trays.

Our endoscopy sales for the nine-month period ended September 30, 2024 were $37.3 million, up 35.6%, when compared to sales in the corresponding period of 2023 of $27.5 million. Sales for the nine-month period ended September 30, 2024 compared to the corresponding period in 2023 were favorably affected by $6.8 million in sales of the EsophyX® Z+ device acquired from EGS in July 2024 as well as by increased sales of our EndoMAXX fully covered esophageal stent, Elation Pulmonary Balloon Dilators, BIG60F Alpha™ inflation device, and AERO Tracheobronchial Stent.

35

Table of Contents

Geographic Sales

Listed below are sales by geography for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands, other than percentage changes):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ | ​ | Three Months Ended | ​ | ​ | ​ | ​ | Nine Months Ended
​ |  | ​ | ​ | ​ | September 30, | ​ | ​ | ​ | ​ | September 30,
​ |  | % Change |  | ​ | 2024 |  | 2023 |  | % Change |  | ​ | 2024 |  | 2023
United States | ​ | 10.1 | % | ​ | $ | 206,492 | ​ | $ | 187,505 | ​ | 9.1 | % | ​ | $ | 587,250 | ​ | $ | 538,447
International | ​ | 4.4 | % | ​ | ​ | 133,353 | ​ | ​ | 127,725 | ​ | 5.0 | % | ​ | ​ | 414,106 | ​ | ​ | 394,404
Total |  | 7.8 | % | ​ | $ | 339,845 | ​ | $ | 315,230 | ​ | 7.3 | % | ​ | $ | 1,001,356 | ​ | $ | 932,851

​

United States Sales. U.S. sales for the three-month period ended September 30, 2024 were $206.5 million, or 60.8% of net sales, up 10.1% when compared to the corresponding period of 2023. The increase in our domestic sales for the three-month period ended September 30, 2024, compared to the corresponding period of 2023 was driven primarily by our U.S. Direct and Endoscopy businesses.

U.S. sales for the nine-month period ended September 30, 2024 were $587.3 million, or 58.6% of net sales, up 9.1% when compared to the corresponding period of 2023. The increase in our domestic sales for the nine-month period ended September 30, 2024, compared to the corresponding period of 2023 was driven primarily by our U.S. Direct and Endoscopy businesses.

International Sales. International sales for the three-month period ended September 30, 2024 were $133.4 million, or 39.2% of net sales, up 4.4% when compared to the corresponding period of 2023 of $127.7 million. The increase in our international sales for the three-month period ended September 30, 2024, compared to the corresponding period of 2023 included increased sales in our EMEA operations of $3.3 million or 5.9%, in our Rest of World (“ROW”) operations of $1.8 million or 14.3%, and in our APAC operations of $0.6 million or 0.9%.

International sales for the nine-month period ended September 30, 2024 were $414.1 million, or 41.4% of net sales, up 5.0% when compared to the corresponding period of 2023 of $394.4 million. The increase in our international sales for the nine-month period ended September 30, 2024, compared to the nine-month period ended September 30, 2023, included increased sales in our EMEA operations of $8.9 million or 5.2%, in our ROW operations of $6.8 million or 19.2%, and in our APAC operations of $4.0 million or 2.1%.

Gross Profit

Our gross profit as a percentage of sales increased to 46.4% for the three-month period ended September 30, 2024, compared to 45.1% for the three-month period ended September 30, 2023. The increase in gross profit percentage was primarily due to increased sales combined with favorable changes in product mix partially offset by higher obsolescence expense and higher intangible amortization expense as a percentage of sales associated with acquisitions.

​

Our gross profit as a percentage of sales increased to 47.0% for the nine-month period ended September 30, 2024, compared to 46.5% for the nine-month period ended September 30, 2023. The increase in gross profit percentage was primarily due to an increase in sales combined with favorable changes in product mix, partially offset by unfavorable manufacturing variances and higher intangible amortization expense as a percentage of sales associated with acquisitions.

36

Table of Contents

Operating Expenses

Selling, General and Administrative Expense. Selling, general and administrative ("SG&A") expenses increased $12.8 million, or 14.7%, for the three-month period ended September 30, 2024 compared to the corresponding period of 2023. As a percentage of sales, SG&A expenses were 29.3% for the three-month period ended September 30, 2024, compared to 27.6% for the corresponding period of 2023. For the three-month period ended September 30, 2024, SG&A expenses increased compared to the corresponding period of 2023, primarily due to an increase in labor related costs associated with headcount additions and employee termination benefits in connection with the integration activities for the EGS Acquisition, increased consulting and legal costs associated with acquisition due diligence, increased advertising and promotional expenses.

SG&A expenses increased $10.7 million, or 3.9%, for the nine-month period ended September 30, 2024 compared to the corresponding period of 2023. As a percentage of sales, SG&A expenses were 28.8% for the nine-month period ended September 30, 2024, compared to 29.8% for the corresponding period of 2023. For the nine-month period ended September 30, 2024, SG&A expenses increased compared to the corresponding period of 2023 primarily due to an increase in labor-related costs in our sales and marketing operations due to increased headcount to support growth and acquisitions, an increase of variable compensation linked to company performance, an increase of stock-based compensation expense associated with new equity grants, and an increased investment in advertising and promotional expenses.

Research and Development Expenses. Research and development (”R&D”) expenses for the three-month period ended September 30, 2024 were $20.5 million, up 4.5%, when compared to R&D expenses in the corresponding period of 2023 of $19.6 million. For the three-month period ended September 30, 2024, R&D expenses increased compared to the corresponding period of 2023 primarily due to increased labor costs due to increased headcount and increased materials for projects, offset partially by decreased regulatory costs related to clinical studies.

R&D expenses for the nine-month period ended September 30, 2024 were $62.3 million, up 1.9%, when compared to R&D expenses in the corresponding period of 2023 of $61.1 million. For the nine-month period ended September 30, 2024, R&D expenses increased compared to the corresponding period of 2023 primarily due to increased labor costs due to increased headcount, increased materials for projects, and increased costs related to clinical studies, offset partially by lower regulatory costs related to implementation of the Medical Device Regulation in the E.U.

Impairment Charges. For the three and nine-month periods ended September 30, 2024, we recognized no impairment charges. For the three-month period ended September 30, 2023, we recognized no impairment charges. For the nine-month period ended September 30, 2023, we recorded impairment charges of $270 thousand due to the acquisition and subsequent write-off of our equity investment in Bluegrass.

Contingent Consideration Expense. For the three and nine-month periods ended September 30, 2024, we recognized contingent consideration expense from changes in the estimated fair value of our contingent consideration obligations stemming from our previously disclosed business acquisitions of $0.1 million and $0.3 million, respectively, compared to contingent consideration expense of $0.6 million and $2.2 million for the three and nine-month periods ended September 30, 2023, respectively. Expense in each period related to changes in the probability and timing of achieving certain revenue and operational milestones, as well as expense for the passage of time.

Acquired In-process Research and Development. For the three and nine-month periods ended September 30, 2024, we recognized no acquired in-process research and development costs. For the three-month period ended September 30, 2023, we recognized no acquired in-process research and development costs. For the nine-month period ended September 30, 2023, we recognized $1.6 million in acquired in-process research and development costs primarily associated with the assets we acquired from Advanced Radiation Therapy, LLC (“ART”) on May 1, 2023.

37

Table of Contents

Operating Income

The following table sets forth our operating income by financial reporting segment for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2024 |  | 2023 |  | 2024 |  | 2023
Operating Income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cardiovascular | ​ | $ | 37,555 | ​ | $ | 32,622 | ​ | $ | 113,374 | ​ | $ | 82,966
Endoscopy | ​ |  | (294) | ​ |  | 2,515 | ​ |  | 5,755 | ​ |  | 7,366
Total operating income | ​ | $ | 37,261 | ​ | $ | 35,137 | ​ | $ | 119,129 | ​ | $ | 90,332

​

Cardiovascular Operating Income. Our cardiovascular operating income for the three-month period ended September 30, 2024 was $37.6 million, compared to cardiovascular operating income in the corresponding period of 2023 of $32.6 million. The increase in cardiovascular operating income during the three-month period ended September 30, 2024 compared to the corresponding period of 2023 was primarily a result of higher sales ($322.9 million compared to $306.1 million), higher gross margin, and lower contingent consideration expense, partially offset by higher SG&A and R&D expenses.

Our cardiovascular operating income for the nine-month period ended September 30, 2024 was $113.4 million, compared to cardiovascular operating income in the corresponding period of 2023 of $83.0 million. The increase in cardiovascular operating income during the nine-month period ended September 30, 2024 compared to the corresponding period of 2023 was primarily a result of higher sales ($964.0 million compared to $905.3 million), higher gross margin, lower acquired in-process research and development charges, lower impairment charges, and lower contingent consideration expense, partially offset by higher SG&A and R&D expenses.

Endoscopy Operating Income (Loss). Our endoscopy operating loss for the three-month period ended September 30, 2024 was ($0.3) million, compared to endoscopy operating income of $2.5 million for the corresponding period of 2023. Our endoscopy operating income for the nine-month period ended September 30, 2024 was $5.8 million, compared to endoscopy operating income of $7.4 million for the corresponding period of 2023. The decrease in endoscopy operating income for the three and nine-month periods ended September 30, 2024 compared to the corresponding periods of 2023 was primarily a result of increased SG&A expenses associated with higher labor related costs due to headcount additions and employee termination benefits in connection with the integration activities for the EGS Acquisition, partially offset by increased sales.

Other Expense – Net

Our other expense for the three-month periods ended September 30, 2024 and 2023 was $0.6 million and $4.9 million, respectively. Our other expense for the nine-month periods ended September 30, 2024 and 2023 was $2.3 million and $9.7 million, respectively. The changes in other expense for the three and nine-month periods ended September 30, 2024 compared to the corresponding periods of 2023 were primarily related to increased interest expense associated with the Convertible Note offering completed in December 2023, partially offset by an increase in interest income associated with higher cash and cash equivalents balances.

38

Table of Contents

Effective Tax Rate

Our provision for income taxes for the three-month periods ended September 30, 2024 and 2023 was a tax expense of $8.2 million and $4.4 million, respectively, which resulted in an effective tax rate of 22.4% and 14.5%, respectively. Our provision for income taxes for the nine-month periods ended September 30, 2024 and 2023 was a tax expense of $24.4 million and $13.8 million, respectively, which resulted in an effective tax rate of 20.9% and 17.2%, respectively. The increase in the effective income tax rate for the three and nine-month periods ended September 30, 2024, when compared to the prior-year period, was primarily due to decreased benefit from discrete items such as share-based compensation and decreased foreign tax credit utilization. The increase in the income tax expense for the nine-month period ended September 30, 2024, when compared to the prior-year period, was primarily due to increased pre-tax book income.

​

Net Income

Our net income for the three-month periods ended September 30, 2024 and 2023 was $28.4 million and $25.8 million, respectively. The increase in our net income for the three-month period ended September 30, 2024 was primarily a result of higher sales, higher gross margin associated and lower contingent consideration expense, partially offset by higher SG&A and R&D expenses and higher income tax expense.

Our net income for the nine-month periods ended September 30, 2024 and 2023 was $92.4 million and $66.8 million, respectively. The increase in our net income for the nine-month period ended September 30, 2024 was the result of several principal factors, including higher sales and gross margin, lower impairment charges, lower acquired in-process research and development charges, and lower contingent consideration expense, partially offset by higher SG&A and R&D expenses and higher income tax expense.

​

LIQUIDITY AND CAPITAL RESOURCES

​

Capital Commitments, Contractual Obligations and Cash Flows

As of September 30, 2024 and December 31, 2023, our current assets exceeded current liabilities by $877.2 million and $904.9 million, respectively, and we had cash, cash equivalents and restricted cash of $525.3 million and $589.1 million, respectively, of which $55.8 million and $48.7 million, respectively, were held by foreign subsidiaries. We currently believe future repatriation of cash and other property held by our foreign subsidiaries will generally not be subject to U.S. federal income tax. As a result, we are not permanently reinvested with respect to our historic unremitted foreign earnings. In addition, cash held by our subsidiary in China is subject to local laws and regulations that require government approval for the transfer of such funds to entities located outside of China. As of September 30, 2024, and December 31, 2023, we had cash, cash equivalents and restricted cash of $23.1 million and $17.6 million, respectively, within our subsidiary in China.

Cash flows provided by operating activities. We generated cash from operating activities of $152.1 million and $82.9 million during the nine-month periods ended September 30, 2024 and 2023, respectively. Significant factors affecting operating cash flows during these periods included:

| ● | Net income was $92.4 million and $66.8 million for the nine-month periods ended September 30, 2024 and 2023, respectively.

| ● | Cash used for inventories was approximately $2.8 million and $34.4 million for the nine-month periods ended September 30, 2024 and 2023, respectively. The increase in inventories during 2023 was principally associated with our strategy to proactively invest in our inventory balances to encourage high customer service levels, as well as to build bridge inventory for production line transfers and increases in safety stock due to vendor supply delays.

| ● | Cash used for trade payables was $6.5 million and $20.3 million for the nine-month periods ended September 30, 2024 and 2023, respectively, due primarily to the timing of payments.

39

Table of Contents

Cash flows used in investing activities. We used cash in investing activities of $154.2 million and $167.0 million for the nine-month periods ended September 30, 2024 and 2023, respectively. We used cash for capital expenditures of property and equipment of $31.7 million and $27.2 million in the nine-month periods ended September 30, 2024 and 2023, respectively. Capital expenditures in each period were primarily related to investments in property and equipment to support development and production of our products. Historically, we have incurred significant expenses in connection with facility construction, production automation, product development and the introduction of new products. We anticipate that we will spend approximately $50 million in 2024 for property and equipment.

Cash outflows for the issuance of notes receivable were $6.6 million for the nine-month period ended September 30, 2024 and were related to loans issued to Selio of $1.7 million, Solo Pace of $2.0 million and Fluidx of $3.0 million. Cash outflows invested in acquisitions for the nine-month period ended September 30, 2024 were $113.7 million and were related to assets acquired from EGS ($105.0 million), assets acquired from SSI ($3.0 million), our investments in Fluidx ($0.3 million) and CrannMed ($3.2 million), and payment of the first deferred payment from our asset purchase agreement with Restore Endosystems, LLC ($2.0 million). Cash outflows invested in acquisitions for the nine-month period ended September 30, 2023 were $138.3 million and were primarily related to payments in our asset purchase agreements with AngioDynamics ($100 million), Bluegrass ($32.7 million) and ART ($1.5 million), and our investment in Solo Pace ($4.0 million).

Cash flows (used in) provided by financing activities. Cash (used in) provided by financing activities for the nine-month periods ended September 30, 2024 and 2023 was $(62.4) million and $86.5 million, respectively. For the nine-month period ended September 30, 2024, we decreased our net borrowings under our Amended Fourth A&R Credit Agreement by $(76.1) million. During the nine-month period ended September 30, 2023 we increased our net borrowings by approximately $88.9 million to finance the acquisitions of AngioDynamics and Bluegrass. We had cash proceeds from the issuance of common stock of $15.4 million and $11.5 million for the nine-month periods ended September 30, 2024 and 2023, respectively, related to the exercise of non-qualified stock options. We completed payment of contingent consideration of $(0.2) million and $(3.5) million for the nine-month periods ended September 30, 2024 and 2023, respectively, principally related to sales milestone payments connected to our acquisitions of Brightwater Medical, Inc. in 2019 and Cianna Medical, Inc. in 2018.

As of September 30, 2024, we had outstanding borrowings of $770.5 million and had issued letter of credit guarantees of $2.4 million, with additional available borrowings of approximately $697 million under the Amended Fourth A&R Credit Agreement, based on the maximum net leverage ratio and the aggregate revolving credit commitment pursuant to the Amended Fourth A&R Credit Agreement. Our interest rate as of September 30, 2024 was a fixed rate of 3.0% on our Convertible Notes and a variable rate of 6.70% with respect to the principal amount outstanding under the Amended Fourth A&R Credit Agreement. Our interest rate as of December 31, 2023 was a fixed rate of 3.0% on our Convertible Notes, a fixed rate of 3.39% on $75 million as a result of an interest rate swap, and a variable floating rate of 7.21% on $24.1 million.

We currently believe that our existing cash balances, anticipated future cash flows from operations and borrowings under our long-term debt agreements will be adequate to fund our current and currently planned future operations for the next twelve months and the foreseeable future. In the event we pursue and complete significant transactions or acquisitions in the future, additional funds may be required to meet our strategic needs, which may require us to raise additional funds in the debt or equity markets.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our financial results are affected by the selection and application of accounting policies and methods. In the nine-month period ended September 30, 2024 there were no changes to the application of critical accounting policies previously disclosed in Part II, Item 7 of the 2023 Annual Report on Form 10-K.

40

Table of Contents

​

​

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

​

This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements in this report, other than statements of historical fact, are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of our management for future operations, any statements concerning proposed new products or services, any statements regarding the integration, development or commercialization of the business or any assets acquired from other parties, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “potential,” “forecasts,” “continue,” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.

​

All subsequent forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. All forward-looking statements included in this report are made as of the date hereof and are based on information available to us as of such date. We assume no obligation to update any forward-looking statement. If we do update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results will likely differ, and could differ materially, from those projected or assumed in the forward-looking statements. Investors are cautioned not to unduly rely on any such forward-looking statements.

NOTICE REGARDING TRADEMARKS

This report includes trademarks, tradenames and service marks that are our property or the property of others. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames.

​

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Quantitative and qualitative disclosures about currency exchange rate risk and interest rate risk are included in Part II, Item 7A "Quantitative and Qualitative Disclosures About Market Risk" in the 2023 Annual Report on Form 10-K. In the nine-month period ended September 30, 2024, there were no material changes from the information provided therein.

​

41

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate disclosure controls and procedures for our company. Consequently, our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of September 30, 2024. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

During the nine-month period ended September 30, 2024, there were no changes in our internal control over financial reporting that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934).

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 10 “Commitments and Contingencies” set forth in the notes to our consolidated financial statements included in Part I, Item 1 of this report.

ITEM 1A. RISK FACTORS

In addition to other information set forth in this report, readers should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" of our 2023 Annual Report on Form 10-K, as updated and supplemented below and in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 (the “Second Quarter 2024 Form 10-Q”). Any of the risk factors disclosed in our reports could materially affect our business, financial condition or future results. The risks described here and in our 2023 Annual Report on Form 10-K and Second Quarter 2024 Form 10-Q are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results. The discussion of the risk factors below updates the corresponding disclosure under the same heading in the 2023 Annual Report on Form 10-K and may contain material changes to the corresponding risk factor discussion in our 2023 Annual Report on Form 10-K.

​

42

Table of Contents

We may incur substantial costs when evaluating, negotiating and closing acquisitions, and our failure to integrate acquired businesses may adversely impact our business and financial results.

​

We seek to supplement our internal growth through strategic acquisitions and transactions. We have completed a series of strategic acquisitions and transactions in recent years, some of which have been significant, such as the AngioDynamics Acquisition and the EGS Acquisition. We are in the process of completing the proposed Cook Acquisition. We continue to evaluate other potential acquisitions and transactions, certain of which may also be significant. We have incurred, and will likely continue to incur, significant expenses in connection with evaluating, negotiating and consummating various acquisition and other transactions.

​

Our integration of acquired businesses requires considerable efforts, including corporate restructuring and the coordination of information technologies, research and development, sales and marketing, operations, regulatory, supply chain, manufacturing, quality systems and finance. These efforts result in additional expenses and involve significant management time. Some of the factors that could affect the success of our acquisitions include, among others, the effectiveness of our due diligence process, our ability to execute our business plan for the acquired companies, the strength of the acquired technology, results of clinical trials, regulatory approvals and reimbursement levels of the acquired products and related procedures, the continued performance of critical transition services, our ability to adequately fund acquired in-process research and development projects and retain key employees and our ability to achieve synergies with our acquired companies, such as increasing sales of our products, achieving cost savings and effectively combining technologies to develop new products. Foreign acquisitions involve unique risks, including those related to integration of operations across different geographies, cultures and languages, currency risks and risks associated with the economic, political, legal and regulatory environment in specific countries. In addition, we have and may in the future acquire less than full ownership interests in other businesses, which involve unique challenges for effective collaboration. Further, other parties that hold remaining ownership interests in such businesses may at any time have economic or business goals that are inconsistent with our goals or the goals of such businesses. Our failure to manage these challenges successfully and coordinate the growth of such businesses or other investments could have an adverse impact on our business and our future growth. In addition, we cannot be certain that the businesses we acquire or invest in will become profitable or remain so, and if our acquisitions or investments are not successful, we may record related asset impairment charges in the future or experience other negative consequences on our operating results.

​

Additionally, past and future acquisitions and transactions may increase the risks of competition we face by, among other things, extending our operations into industry segments and product lines where we have few existing customers or qualified sales personnel and limited expertise. Further, as a result of certain acquisitions, we are selling capital equipment, in addition to our historical sales of disposable medical devices. The sale of capital equipment may create additional risks and potential liability, which may negatively affect our business, operations or financial condition.

​

In addition, we may not realize competitive advantages, synergies or other benefits anticipated in connection with any such acquisition or other transaction. If we do not adequately identify and value targets for, or manage issues related to, acquisitions and other transactions, such transactions may not produce the anticipated benefits and have an adverse effect on our business, operations or financial condition. We have incurred expenses in connection with the disposition of businesses and assets which we acquired but determined that they did not produce the benefits contemplated at the time of acquisition. We may incur similar expenses in the future.

​

ITEM 5. OTHER INFORMATION

During the fiscal quarter ended September 30, 2024, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408.

​

43

Table of Contents

ITEM 6. EXHIBITS

Exhibit No. |  | Description
2.1* | ​ | Asset Purchase Agreement, dated September 16, 2024, by and between Merit Medical Systems, Inc. and Cook Medical Holdings LLC.
3.1† | ​ | Second Amended and Restated Articles of Incorporation.
3.2† | ​ | Fourth Amended and Restated Bylaws.
31.1 | ​ | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 | ​ | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 | ​ | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 | ​ | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 | ​ | The following financial information from the quarterly report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive Income (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) related Condensed Notes to the Unaudited Consolidated Financial Statements, tagged in detail.
104 |  | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

​

* Portions of this exhibit have been omitted.

† These exhibits are incorporated herein by reference.

​

​

​

​

44

Table of Contents

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​ | ​ | ​ | ​
​ | MERIT MEDICAL SYSTEMS, INC.
​ | ​ | ​
Date: October 30, 2024 | By: | /s/ FRED P. LAMPROPOULOS
​ | ​ | Fred P. Lampropoulos
​ | ​ | Chief Executive Officer
​ | ​ | ​ | ​
Date: October 30, 2024 | By: | /s/ RAUL PARRA
​ | ​ | Raul Parra
​ | ​ | Chief Financial Officer and Treasurer
​ | ​ | ​ | ​
​ | ​ | ​ | ​

​

​

​

​

​

​

45